No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
(11c)pe2i |
- |
- |
- |
- |
1件: 6 |
2 |
(2-chloro-5-[11c]methoxy-n-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide) |
- |
- |
- |
- |
1件: 6 |
3 |
(3beta, 5beta, 25r)-spirostan-3-ol |
- |
- |
- |
- |
1件: 6 |
4 |
(3ß, 5ß, 25r)-spirostan-3-ol |
- |
- |
- |
- |
1件: 6 |
5 |
(6s)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol |
- |
- |
- |
- |
1件: 6 |
6 |
(r)-troloxamide quinone |
- |
- |
- |
- |
1件: 6 |
7 |
(s)- 2- amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol |
- |
- |
- |
- |
1件: 6 |
8 |
(s)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate |
- |
- |
- |
- |
1件: 6 |
9 |
0 mg tropicamide |
Tropicamide |
D00397 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 6 |
10 |
0.3 mg tropicamide |
Tropicamide |
D00397 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 6 |
11 |
0.9% sodium chloride |
Sodium chloride |
D02056 |
- |
- |
3件: 6, 14, 51 |
12 |
0.9% sodium chloride (normal saline) |
Sodium chloride |
D02056 |
- |
- |
1件: 6 |
13 |
009-0 |
- |
- |
- |
- |
1件: 6 |
14 |
009-1 |
- |
- |
- |
- |
1件: 6 |
15 |
009-2 |
- |
- |
- |
- |
1件: 6 |
16 |
009-3 |
- |
- |
- |
- |
1件: 6 |
17 |
009-4 |
- |
- |
- |
- |
1件: 6 |
18 |
009-5 |
- |
- |
- |
- |
1件: 6 |
19 |
009-a0 |
- |
- |
- |
- |
1件: 6 |
20 |
009-a1 |
- |
- |
- |
- |
1件: 6 |
21 |
009-a2 |
- |
- |
- |
- |
1件: 6 |
22 |
009-a3 |
- |
- |
- |
- |
1件: 6 |
23 |
1 mg qd to 15 mg qd pf-06649751 |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
24 |
1 mg qd to 7 mg qd pf-06649751 (if de-escalated in parent study) |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
25 |
1 mg tropicamide |
Tropicamide |
D00397 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 6 |
26 |
1. tesofensine (ns 2330) |
Tesofensine |
- |
- |
- |
1件: 6 |
27 |
1.0 mg rasagiline mesylate |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
28 |
11c-pbr28 |
- |
- |
- |
- |
1件: 6 |
29 |
11c-raclopride |
Raclopride |
- |
- |
- |
1件: 6 |
30 |
15 mg qd de-escalated to 7 mg qd pf-06649751 in parent study remain at 7 mg qd |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
31 |
15 mg qd pf-06649751 |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
32 |
15o h2o |
- |
- |
- |
- |
1件: 6 |
33 |
18-fdtbz |
- |
- |
- |
- |
1件: 6 |
34 |
18f florbetaben |
- |
- |
- |
- |
1件: 6 |
35 |
18f- dtbz |
- |
- |
- |
- |
1件: 6 |
36 |
18f-av-133 |
Florbenazine f-18 |
- |
- |
- |
1件: 6 |
37 |
18f-av-45 |
- |
- |
- |
- |
2件: 6, 127 |
38 |
18f-dopa |
- |
- |
- |
- |
2件: 6, 75 |
39 |
18f-dopa pet |
- |
- |
- |
- |
1件: 6 |
40 |
18f-dtbz |
- |
- |
- |
- |
1件: 6 |
41 |
18f-dtbz av-133 |
- |
- |
- |
- |
1件: 6 |
42 |
18f-fdg |
Fludeoxyglucose f-18 |
- |
- |
- |
7件: 6, 13, 46, 53, 84, 127, 300 |
43 |
1[(6- allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- |
- |
- |
- |
- |
1件: 6 |
44 |
1[(6- allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea |
- |
- |
- |
- |
1件: 6 |
45 |
1[(6- allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- |
- |
- |
- |
- |
1件: 6 |
46 |
1[(6- allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea |
- |
- |
- |
- |
1件: 6 |
47 |
2 mg perampanel |
Perampanel |
D08964 |
4件: GRIA1, GRIA2, GRIA3, GRIA4 |
13件: Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Transcriptional misregulation in cancer, cAMP signaling pathway |
1件: 6 |
48 |
200 mg bia 6-512 |
- |
- |
- |
- |
1件: 6 |
49 |
207-3120 |
- |
- |
- |
- |
1件: 6 |
50 |
240mg amantadine hcl er tablets |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
51 |
25330 |
- |
- |
- |
- |
1件: 6 |
52 |
3 mg qd to 15 mg qd pf-06649751 |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
53 |
3 mg qd to 7 mg qd pf-06649751 (de-escalated in parent study) |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
54 |
3 mg tropicamide |
Tropicamide |
D00397 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 6 |
55 |
3- (9,10- didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate |
- |
- |
- |
- |
1件: 6 |
56 |
320mg amantadine hcl er tablets |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
57 |
4 mg perampanel |
Perampanel |
D08964 |
4件: GRIA1, GRIA2, GRIA3, GRIA4 |
13件: Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Transcriptional misregulation in cancer, cAMP signaling pathway |
1件: 6 |
58 |
6abeta - apomorphine-10,11-diol hydrochloride hemihydrate |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
59 |
6aß - apomorphine-10,11-diol hydrochloride hemihydrate |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
60 |
7 mg qd to 15 mg qd pf-06649751 |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
61 |
7 mg qd to 7 mg qd pf-06649751 (de-escalated in parent study) |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
62 |
7-beta-hydroxyepiandrosterone |
- |
- |
- |
- |
1件: 6 |
63 |
[11c]pbr28 |
- |
- |
- |
- |
1件: 6 |
64 |
[11c]pxt012253 |
- |
- |
- |
- |
1件: 6 |
65 |
[11c]smw139 |
- |
- |
- |
- |
1件: 6 |
66 |
[123i] 5-ia |
- |
- |
- |
- |
1件: 6 |
67 |
[123i] ibvm and spect imaging |
- |
- |
- |
- |
1件: 6 |
68 |
[123i] mzint injection and serial dynamic spect imaging |
- |
- |
- |
- |
1件: 6 |
69 |
[123i]-ibvm |
- |
- |
- |
- |
1件: 6 |
70 |
[123i]b-cit |
- |
- |
- |
- |
1件: 6 |
71 |
[123i]b-cit spect imaging |
- |
- |
- |
- |
1件: 6 |
72 |
[123i]beta cit |
- |
- |
- |
- |
1件: 6 |
73 |
[123i]beta cit and spect imaging |
- |
- |
- |
- |
1件: 6 |
74 |
[123i]beta-cit |
- |
- |
- |
- |
1件: 6 |
75 |
[123i]beta-cit and spect imaging |
- |
- |
- |
- |
1件: 6 |
76 |
[123i]clinde |
- |
- |
- |
- |
2件: 6, 13 |
77 |
[123i]mni-420 |
- |
- |
- |
- |
2件: 6, 8 |
78 |
[123i]ß cit |
- |
- |
- |
- |
1件: 6 |
79 |
[123i]ß cit and spect imaging |
- |
- |
- |
- |
1件: 6 |
80 |
[123i]ß-cit |
- |
- |
- |
- |
1件: 6 |
81 |
[123i]ß-cit and spect imaging |
- |
- |
- |
- |
1件: 6 |
82 |
[14c]-bia 9-1067 |
- |
- |
- |
- |
1件: 6 |
83 |
[15o]h2o |
- |
- |
- |
- |
1件: 6 |
84 |
[18f] cfpypb |
- |
- |
- |
- |
1件: 6 |
85 |
[18f] lbt-999 pet |
- |
- |
- |
- |
1件: 6 |
86 |
[18f] pbr06 |
- |
- |
- |
- |
2件: 6, 13 |
87 |
[18f]-(e)-n-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane |
- |
- |
- |
- |
1件: 6 |
88 |
[18f]-feppa |
- |
- |
- |
- |
2件: 6, 13 |
89 |
[18f]dpa-714 pet scan |
- |
- |
- |
- |
1件: 6 |
90 |
[18f]fdopa pet/ct |
- |
- |
- |
- |
1件: 6 |
91 |
[18f]fe-pe2i |
- |
- |
- |
- |
1件: 6 |
92 |
[18f]fpeb |
- |
- |
- |
- |
3件: 6, 8, 206 |
93 |
[18f]mk-9470 |
- |
- |
- |
- |
1件: 6 |
94 |
[18f]mni-1126 |
- |
- |
- |
- |
1件: 6 |
95 |
[18f]mppf |
- |
- |
- |
- |
1件: 6 |
96 |
[18f]nos |
- |
- |
- |
- |
1件: 6 |
97 |
[18f]p17-059 |
- |
- |
- |
- |
1件: 6 |
98 |
[18f]t807 ([18f]mni-777) |
- |
- |
- |
- |
2件: 5, 6 |
99 |
Ab1010 |
Masitinib |
D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
6件: 2, 5, 6, 13, 46, 96 |
100 |
Abbv-0805 |
- |
- |
- |
- |
1件: 6 |
101 |
Abbv-951 |
- |
- |
- |
- |
1件: 6 |
102 |
Abt-slv187 |
- |
- |
- |
- |
1件: 6 |
103 |
Acamprosate |
Acamprosate |
D02780, D07058 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
2件: 6, 206 |
104 |
Accordion pill carbidopa/levodopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
105 |
Accordion pill™ carbidopa/levodopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
106 |
Accordion pill™ carbidopa/levodopa 50/400 mg |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
107 |
Accordion pill™ carbidopa/levodopa 50/500 mg |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
108 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
109 |
Acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
14件: 6, 13, 19, 20, 49, 51, 58, 85, 94, 111, 164, 233, 298, 299 |
110 |
Acp-103 |
- |
- |
- |
- |
1件: 6 |
111 |
Acr325 |
Acr325 |
- |
- |
- |
1件: 6 |
112 |
Active comparator |
- |
- |
- |
- |
2件: 6, 46 |
113 |
Active drug (biib014) at 10, 30, 100, or 300 mg once daily. |
Dihydrotachysterol |
D00299 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 6 |
114 |
Active drug: pimavanserin 17mg (2 strength tablets) |
Pimavanserin |
- |
- |
- |
1件: 6 |
115 |
Active investigational treatment ent-01 |
- |
- |
- |
- |
1件: 6 |
116 |
Ad-810n (zonisamide) |
Zonisamide |
D00538 |
8件: CACNA1G, CACNA1H, CACNA1I, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
11件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dopaminergic synapse, GnRH secretion, MAPK signaling pathway, Taste transduction, Type II diabetes mellitus |
1件: 6 |
117 |
Adjuvant without active component |
- |
- |
- |
- |
2件: 6, 17 |
118 |
Administration of stable isotope-labelled leucine- |
L-leucine |
D00030 |
- |
- |
1件: 6 |
119 |
Ads-5102 |
- |
- |
- |
- |
2件: 6, 13 |
120 |
Ads-5102 (extended release amantadine hcl) |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
121 |
Adx48621 |
- |
- |
- |
- |
1件: 6 |
122 |
Affitope® pd01a |
- |
- |
- |
- |
1件: 6 |
123 |
Affitope® pd01a + adjuvant |
- |
- |
- |
- |
2件: 6, 17 |
124 |
Afq056 |
- |
- |
- |
- |
3件: 6, 8, 206 |
125 |
Afq056 with l-dopa |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
126 |
Agomelatine |
Agomelatine |
D02578 |
3件: HTR2C, MTNR1A, MTNR1B |
6件: Calcium signaling pathway, Circadian entrainment, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse |
1件: 6 |
127 |
Agomelatine or piacebo |
Agomelatine |
D02578 |
3件: HTR2C, MTNR1A, MTNR1B |
6件: Calcium signaling pathway, Circadian entrainment, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse |
1件: 6 |
128 |
Allogeneic bone marrow-derived mscs |
- |
- |
- |
- |
1件: 6 |
129 |
Allopurinol |
Allopurinol |
D00224 |
1件: XDH |
5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
6件: 6, 46, 57, 66, 96, 97 |
130 |
Altropane |
Altropane |
- |
- |
- |
1件: 6 |
131 |
Altropane® |
Altropane |
- |
- |
- |
1件: 6 |
132 |
Amantadine |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
4件: 6, 8, 13, 127 |
133 |
Amantadine 300 mg |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
134 |
Amantadine hcl er |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
135 |
Amantadine hcl extended release |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
136 |
Amantadine hydrochloride |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
137 |
Amantadine sulfate |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
138 |
Ambrosan 60mg tablets |
- |
- |
- |
- |
1件: 6 |
139 |
Ambroxol |
Ambroxol |
D07442 |
- |
- |
2件: 6, 19 |
140 |
Ambroxol hydrochloride |
Ambroxol |
D07442 |
- |
- |
1件: 6 |
141 |
Amoxicillin |
Amoxicillin |
D00229, D02925, D07452 |
- |
- |
6件: 6, 46, 63, 96, 97, 222 |
142 |
Ampyra first, |
- |
- |
- |
- |
1件: 6 |
143 |
Anavex2-73 |
- |
- |
- |
- |
2件: 6, 156 |
144 |
Anti-parkinson medication |
- |
- |
- |
- |
4件: 5, 6, 7, 17 |
145 |
Ap-cd/ld |
- |
- |
- |
- |
1件: 6 |
146 |
Ap09004 |
- |
- |
- |
- |
1件: 6 |
147 |
Apl-130277 |
- |
- |
- |
- |
1件: 6 |
148 |
Aplindore |
Aplindore |
- |
- |
- |
1件: 6 |
149 |
Aplindore mr tablets |
Aplindore |
- |
- |
- |
1件: 6 |
150 |
Apo-go |
- |
- |
- |
- |
1件: 6 |
151 |
Apo-go® |
- |
- |
- |
- |
1件: 6 |
152 |
Apokinon |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
153 |
Apokyn |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
154 |
Apomorphine |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
155 |
Apomorphine 0.25% (2.5mg/ml) |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
156 |
Apomorphine hcl injection |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
157 |
Apomorphine hydrochloride |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
158 |
Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
159 |
Apomorphine hydrochloride 2.8mg inhalation powder, pre-dispensed |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
160 |
Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
161 |
Apomorphine hydrochloride 5.8 mg inhalation powder, pre-dispensed |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
162 |
Apomorphine hydrocloride |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
163 |
Apomorphine hydrocloride hemihydrate |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
164 |
Apomorphine infusion |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
165 |
Apomorphine nasal powder |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
166 |
Aqw051 |
- |
- |
- |
- |
1件: 6 |
167 |
Aricept |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
4件: 6, 13, 78, 124 |
168 |
Aricept 5 mg-filmtabletten |
- |
- |
- |
- |
1件: 6 |
169 |
Aricept 5mg-filmtabletten |
- |
- |
- |
- |
1件: 6 |
170 |
Aripiprazole |
Aripiprazole |
D01164 |
4件: DRD2, DRD3, HTR1A, HTR2A |
12件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
2件: 6, 206 |
171 |
Armodafinil |
Armodafinil |
D03215 |
1件: SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
3件: 6, 13, 84 |
172 |
At 10 |
Dihydrotachysterol |
D00299 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 6 |
173 |
Atm fog in pd |
- |
- |
- |
- |
1件: 6 |
174 |
Atomoxetine |
Atomoxetine |
D02574, D07473 |
1件: SLC6A2 |
1件: Synaptic vesicle cycle |
3件: 6, 8, 13 |
175 |
Atypical antipsychotics |
- |
- |
- |
- |
1件: 6 |
176 |
Autologous mesenchymal stem cells |
- |
- |
- |
- |
5件: 2, 6, 13, 17, 46 |
177 |
Av-101 |
- |
- |
- |
- |
1件: 6 |
178 |
Avalox |
Moxifloxacin |
D00874, D08237 |
- |
- |
1件: 6 |
179 |
Avalox - 400 mg compresse rivestite con film 5 compresse in blister pp/al |
Moxifloxacin |
D00874, D08237 |
- |
- |
1件: 6 |
180 |
Ave8112 |
- |
- |
- |
- |
1件: 6 |
181 |
Avp-923 |
- |
- |
- |
- |
3件: 2, 6, 13 |
182 |
Avp-923-45 |
- |
- |
- |
- |
1件: 6 |
183 |
Azd3241 |
- |
- |
- |
- |
2件: 6, 17 |
184 |
Azd3241 300 mg bid |
- |
- |
- |
- |
1件: 6 |
185 |
Azd3241 600 mg bid |
- |
- |
- |
- |
1件: 6 |
186 |
Azd3241 alternative titration scheme with formulation 1 or 2 |
- |
- |
- |
- |
1件: 6 |
187 |
Azd3241 er formulation 1 |
- |
- |
- |
- |
1件: 6 |
188 |
Azd3241 extended release tablets 100 mg |
- |
- |
- |
- |
1件: 6 |
189 |
Azd3241 extended release tablets 25 mg |
- |
- |
- |
- |
1件: 6 |
190 |
Azilect |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
3件: 5, 6, 17 |
191 |
Azilect® |
- |
- |
- |
- |
1件: 6 |
192 |
B-cit and spect imaging |
- |
- |
- |
- |
1件: 6 |
193 |
B6, b12, l-methylfolate |
Levomefolic acid |
D09353 |
- |
- |
1件: 6 |
194 |
Balance |
Isoxaflutole |
- |
- |
- |
8件: 5, 6, 13, 18, 81, 113, 149, 299 |
195 |
Bavisant |
Bavisant |
D09870 |
1件: HRH3 |
1件: Neuroactive ligand-receptor interaction |
1件: 6 |
196 |
Bavisant dihydrochloride monohydrate |
Bavisant |
D09870 |
1件: HRH3 |
1件: Neuroactive ligand-receptor interaction |
1件: 6 |
197 |
Bavisant hydrochloride monohydrate |
Bavisant |
D09870 |
1件: HRH3 |
1件: Neuroactive ligand-receptor interaction |
1件: 6 |
198 |
Bee venom |
- |
- |
- |
- |
1件: 6 |
199 |
Ben-2001 |
- |
- |
- |
- |
1件: 6 |
200 |
Benserazide |
Benserazide |
D03082 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
201 |
Benserazide hydrochloride |
Benserazide |
D03082 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
202 |
Benzofuran |
Benzofuran |
- |
- |
- |
1件: 6 |
203 |
Best medical treatment |
- |
- |
- |
- |
1件: 6 |
204 |
Bf 2.649 |
- |
- |
- |
- |
1件: 6 |
205 |
Bf2.649 |
- |
- |
- |
- |
1件: 6 |
206 |
Bf2.649 (pitolisant) |
Pitolisant |
D10749 |
1件: HRH3 |
1件: Neuroactive ligand-receptor interaction |
1件: 6 |
207 |
Bi-sifrol® |
- |
- |
- |
- |
1件: 6 |
208 |
Bia 3-202 |
- |
- |
- |
- |
1件: 6 |
209 |
Bia 3-202 (200 mg) |
- |
- |
- |
- |
1件: 6 |
210 |
Bia 6-512 |
- |
- |
- |
- |
1件: 6 |
211 |
Bia 6-512 100 mg |
- |
- |
- |
- |
1件: 6 |
212 |
Bia 6-512 100 mg dose |
- |
- |
- |
- |
1件: 6 |
213 |
Bia 6-512 200 mg dose |
- |
- |
- |
- |
1件: 6 |
214 |
Bia 6-512 25 mg |
- |
- |
- |
- |
1件: 6 |
215 |
Bia 6-512 25 mg dose |
- |
- |
- |
- |
1件: 6 |
216 |
Bia 6-512 400 mg |
- |
- |
- |
- |
1件: 6 |
217 |
Bia 6-512 50 mg dose |
- |
- |
- |
- |
1件: 6 |
218 |
Bia 9-1067 |
- |
- |
- |
- |
1件: 6 |
219 |
Bia 9-1067 (test) |
- |
- |
- |
- |
1件: 6 |
220 |
Bia 9-1067 15 mg |
- |
- |
- |
- |
1件: 6 |
221 |
Bia 9-1067 25 mg |
- |
- |
- |
- |
1件: 6 |
222 |
Bia 9-1067 30 mg |
- |
- |
- |
- |
1件: 6 |
223 |
Bia 9-1067 5 mg |
- |
- |
- |
- |
1件: 6 |
224 |
Bia 9-1067 micronized |
- |
- |
- |
- |
1件: 6 |
225 |
Bia 9-1067 non-micronized |
- |
- |
- |
- |
1件: 6 |
226 |
Biib014 |
- |
- |
- |
- |
1件: 6 |
227 |
Biib054 |
- |
- |
- |
- |
1件: 6 |
228 |
Biib094 |
- |
- |
- |
- |
1件: 6 |
229 |
Bisphosphonates |
- |
- |
- |
- |
2件: 6, 274 |
230 |
Bone marrow derived mesenchymal stem cells |
- |
- |
- |
- |
2件: 6, 60 |
231 |
Bont-a |
- |
- |
- |
- |
1件: 6 |
232 |
Botox |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
4件: 6, 13, 149, 226 |
233 |
Botulinum toxin |
- |
- |
- |
- |
1件: 6 |
234 |
Botulinum toxin type a |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
10件: 2, 5, 6, 7, 13, 15, 17, 70, 113, 149 |
235 |
Botulinum toxin type b |
Botulinum toxin type b |
D02735 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
3件: 2, 6, 51 |
236 |
Botulinum toxin type b (myobloc) |
Botulinum toxin type b |
D02735 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
2件: 2, 6 |
237 |
Botulinum toxin: xeomin |
- |
- |
- |
- |
1件: 6 |
238 |
Bromocriptine |
Bromocriptine |
D00780, D03165 |
2件: DRD2, PRL |
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
2件: 6, 74 |
239 |
Bromocriptine and other dopamine agonists |
Bromocriptine |
D00780, D03165 |
2件: DRD2, PRL |
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
240 |
Btrx-246040 |
- |
- |
- |
- |
1件: 6 |
241 |
Btx-a |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
1件: 6 |
242 |
Bumetanide |
Bumetanide |
D00247 |
1件: SLC12A2 |
3件: Pancreatic secretion, Salivary secretion, Vibrio cholerae infection |
2件: 6, 158 |
243 |
Bumetanide white, oblong, scored tablet |
Bumetanide |
D00247 |
1件: SLC12A2 |
3件: Pancreatic secretion, Salivary secretion, Vibrio cholerae infection |
1件: 6 |
244 |
Bupleurum+ginkgo |
Ginkgo biloba |
- |
- |
- |
1件: 6 |
245 |
Buspirone |
Buspirone |
D00702, D07593 |
2件: DRD2, HTR1A |
10件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
2件: 6, 51 |
246 |
Buspirone hydrochloride |
Buspirone |
D00702, D07593 |
2件: DRD2, HTR1A |
10件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
1件: 6 |
247 |
Butylphthalide |
Butylphthalide |
- |
- |
- |
2件: 2, 6 |
248 |
Byetta 5 micrograms |
Exenatide |
D04121 |
1件: GLP1R |
3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 6 |
249 |
Cabaseril |
Cabergoline |
D00987 |
2件: DRD2, PRL |
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
250 |
Cabaseril, 1,0 mg tablette |
Cabergoline |
D00987 |
2件: DRD2, PRL |
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
251 |
Cabaseril, 2,0 mg tablette |
Cabergoline |
D00987 |
2件: DRD2, PRL |
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
252 |
Cabergoline |
Cabergoline |
D00987 |
2件: DRD2, PRL |
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
3件: 6, 74, 75 |
253 |
Caffeine |
Caffeine |
D00528, D01453 |
11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A |
22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
6件: 2, 6, 46, 78, 96, 97 |
254 |
Caffeine 100-200 mg bid |
Caffeine |
D00528, D01453 |
11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A |
22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
255 |
Caffeine alkaloid |
Caffeine |
D00528, D01453 |
11件: ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A |
22件: Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
256 |
Calcium |
Calcium |
- |
- |
- |
24件: 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
257 |
Cannabidiol |
Cannabidiol |
D10915 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
13件: 6, 13, 46, 95, 96, 97, 140, 144, 145, 157, 158, 193, 271 |
258 |
Cannabis |
Medical cannabis |
- |
- |
- |
6件: 2, 6, 13, 90, 96, 97 |
259 |
Cannabis oil |
Medical cannabis |
- |
- |
- |
1件: 6 |
260 |
Cannabis, medical |
Medical cannabis |
- |
- |
- |
5件: 2, 6, 13, 96, 97 |
261 |
Capsaicin |
Capsaicin |
D00250 |
1件: TRPV1 |
2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
6件: 2, 6, 19, 86, 113, 226 |
262 |
Capsaicin vapor |
Capsaicin |
D00250 |
1件: TRPV1 |
2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 6 |
263 |
Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
264 |
Capture |
Bifenthrin |
- |
- |
- |
2件: 6, 46 |
265 |
Carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
8件: 2, 4, 6, 13, 17, 90, 164, 201 |
266 |
Carbidopa 20 mg |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
267 |
Carbidopa 27.5 mg |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
268 |
Carbidopa 65 mg capsule |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
269 |
Carbidopa and levodopa 25mg/100mg |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
270 |
Carbidopa fu |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
271 |
Carbidopa levodopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
272 |
Carbidopa monohydrate |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
273 |
Carbidopa, levodopa, entacapone |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
274 |
Carbidopa- levodopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
275 |
Carbidopa-levodopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
3件: 2, 4, 6 |
276 |
Carbidopa/l-dopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
277 |
Carbidopa/l-dopa/entacapone |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
278 |
Carbidopa/levodopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
279 |
Carbidopa/levodopa, immediate release |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
280 |
Carbidopa/levodopa/entacapone |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
281 |
Carbon |
Activated charcoal |
D03251 |
- |
- |
7件: 6, 46, 85, 86, 96, 97, 298 |
282 |
Carnosine |
Carnosine |
- |
- |
- |
2件: 6, 13 |
283 |
Carnosine supplementation |
Carnosine |
- |
- |
- |
1件: 6 |
284 |
Carvedilol |
Carvedilol |
D00255, D03415 |
5件: ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2 |
12件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
4件: 6, 57, 86, 113 |
285 |
Catapres ampoules |
Clonidine |
D00281, D00604 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 6 |
286 |
Cd-ld cr |
- |
- |
- |
- |
1件: 6 |
287 |
Cd-ld ir |
- |
- |
- |
- |
1件: 6 |
288 |
Cdnf |
- |
- |
- |
- |
1件: 6 |
289 |
Ceftriaxone |
Ceftriaxone |
D00924, D07659 |
- |
- |
3件: 2, 6, 97 |
290 |
Cep-1347 |
- |
- |
- |
- |
1件: 6 |
291 |
Cep-1347 10mg |
- |
- |
- |
- |
1件: 6 |
292 |
Cep-1347 50mg |
- |
- |
- |
- |
1件: 6 |
293 |
Cep1347 |
Cep1347 |
- |
- |
- |
1件: 6 |
294 |
Cep1347 25mg |
Cep1347 |
- |
- |
- |
1件: 6 |
295 |
Cere-120 |
- |
- |
- |
- |
1件: 6 |
296 |
Cere-120: adeno-associated virus delivery of neurturin |
- |
- |
- |
- |
1件: 6 |
297 |
Cerebral dopamine neurotrophic factor |
Dopamine |
D00633, D07870 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
298 |
Ceretec |
Technetium tc-99m exametazime |
D02284 |
- |
- |
1件: 6 |
299 |
Ceretec (tm) estabilizado |
Technetium tc-99m exametazime |
D02284 |
- |
- |
1件: 6 |
300 |
Champix |
Varenicline |
D08669 |
2件: CHRNA4, CHRNB2 |
3件: Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction |
1件: 6 |
301 |
Chloride |
Chloride ion |
- |
- |
- |
17件: 6, 11, 13, 14, 34, 46, 51, 96, 97, 127, 168, 193, 227, 228, 288, 297, 299 |
302 |
Chocolate |
Cocoa |
- |
- |
- |
1件: 6 |
303 |
Cipralex |
- |
- |
- |
- |
1件: 6 |
304 |
Cjh1 (clr4001) |
- |
- |
- |
- |
1件: 6 |
305 |
Clarithromycin |
Clarithromycin |
D00276 |
- |
- |
8件: 6, 63, 84, 96, 97, 222, 228, 299 |
306 |
Clarium |
Loratadine |
D00364 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 6 |
307 |
Clarium 50 mg retardtabletten |
Loratadine |
D00364 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 6 |
308 |
Clartihromycin, amoxicillin, and omeprazole |
Amoxicillin |
D00229, D02925, D07452 |
- |
- |
1件: 6 |
309 |
Clonazepam |
Clonazepam |
D00280 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 6 |
310 |
Clonidine |
Clonidine |
D00281, D00604 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
2件: 6, 78 |
311 |
Clonidine hydrochloride |
Clonidine |
D00281, D00604 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
2件: 6, 78 |
312 |
Clozapine |
Clozapine |
D00283 |
11件: ADRA2A, ADRA2B, ADRA2C, DRD4, HTR2A, HTR2C, HTR3A, HTR3B, HTR3C, HTR3D, HTR3E |
8件: Calcium signaling pathway, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction, cGMP-PKG signaling pathway |
1件: 6 |
313 |
Cocoa |
Cocoa |
- |
- |
- |
1件: 6 |
314 |
Coenzyme q10 |
Ubidecarenone |
D01065 |
- |
- |
10件: 2, 6, 8, 10, 46, 57, 113, 193, 214, 215 |
315 |
Coenzyme q10 nanodispersion (nanoquinone) |
Ubidecarenone |
D01065 |
- |
- |
1件: 6 |
316 |
Coenzyme q10 with vitamin e |
Vitamin e |
D02331 |
- |
- |
1件: 6 |
317 |
Cogane™ (pym50028) |
- |
- |
- |
- |
1件: 6 |
318 |
Cohort 1:nilotinib oral capsules (150mg or 300mg) |
Nilotinib |
D08953 |
4件: ABL1, KIT, PDGFRA, PDGFRB |
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
1件: 6 |
319 |
Cohort 2: nilotinib oral capsules (dose to be determined from cohort 1) |
Nilotinib |
D08953 |
4件: ABL1, KIT, PDGFRA, PDGFRB |
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
1件: 6 |
320 |
Combination injection of epo and g-csf |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
1件: 6 |
321 |
Comparator: carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
322 |
Comparator: levodopa |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
323 |
Comtan |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
324 |
Comtan® |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
325 |
Comtess |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
326 |
Comtess® |
- |
- |
- |
- |
1件: 6 |
327 |
Continuous intrajejunal infusion of levodopa-carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
328 |
Continuous release dopamine agonists |
Dopamine |
D00633, D07870 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
329 |
Control |
Chloroxylenol |
D03473 |
- |
- |
4件: 6, 13, 46, 168 |
330 |
Controlled-release levodopa / carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
331 |
Coq10 |
Ubidecarenone |
D01065 |
- |
- |
3件: 5, 6, 8 |
332 |
Creatine |
Creatine |
- |
- |
- |
12件: 1, 2, 5, 6, 8, 13, 46, 49, 50, 113, 156, 201 |
333 |
Cu(ii)atsm |
- |
- |
- |
- |
2件: 2, 6 |
334 |
Cvd00118-e |
- |
- |
- |
- |
1件: 6 |
335 |
Cvt-301 |
- |
- |
- |
- |
1件: 6 |
336 |
Cvt-301 (dose level 1) |
- |
- |
- |
- |
1件: 6 |
337 |
Cvt-301 (dose level 2) |
- |
- |
- |
- |
1件: 6 |
338 |
Cvt-301 35mg |
- |
- |
- |
- |
1件: 6 |
339 |
Cvt-301 50mg |
- |
- |
- |
- |
1件: 6 |
340 |
Cvt-301 high dose |
- |
- |
- |
- |
1件: 6 |
341 |
Cvt-301 low dose |
- |
- |
- |
- |
1件: 6 |
342 |
Cvt-301, lip |
- |
- |
- |
- |
1件: 6 |
343 |
Cvxl-0107 |
- |
- |
- |
- |
1件: 6 |
344 |
Cx-8998 |
- |
- |
- |
- |
1件: 6 |
345 |
Cyberknife |
- |
- |
- |
- |
1件: 6 |
346 |
Cymbalta |
Duloxetine |
D01179, D07880 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 6, 13, 49 |
347 |
Cysteine |
L-cysteine |
D00026, D02326 |
- |
- |
9件: 6, 13, 19, 84, 85, 88, 90, 254, 296 |
348 |
Cystoscopic injection of botox into the urinary bladder |
- |
- |
- |
- |
1件: 6 |
349 |
D-serine |
Serine |
D00016 |
- |
- |
1件: 6 |
350 |
D-serine (~2g/day) |
Serine |
D00016 |
- |
- |
1件: 6 |
351 |
Da-9701 |
- |
- |
- |
- |
1件: 6 |
352 |
Da-9805 45mg |
- |
- |
- |
- |
1件: 6 |
353 |
Da-9805 90mg |
- |
- |
- |
- |
1件: 6 |
354 |
Dacepton 5 mg/ml |
- |
- |
- |
- |
1件: 6 |
355 |
Dacepton 5 mg/ml infuusioneste, liuos |
- |
- |
- |
- |
1件: 6 |
356 |
Darifenacin |
Darifenacin |
D01699, D03654 |
1件: CHRM3 |
9件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction |
2件: 6, 13 |
357 |
Dark chocolate (85% cocoa) |
Cocoa |
- |
- |
- |
1件: 6 |
358 |
Date |
Date |
- |
- |
- |
3件: 6, 88, 113 |
359 |
Datscan |
Ioflupane i-123 |
D10014 |
- |
- |
3件: 2, 5, 6 |
360 |
Datscan™ |
- |
- |
- |
- |
1件: 6 |
361 |
Dc158am |
- |
- |
- |
- |
1件: 6 |
362 |
Deanol |
Deanol |
D07777 |
- |
- |
1件: 6 |
363 |
Deanol pyroglutamate |
Deanol |
D07777 |
- |
- |
1件: 6 |
364 |
Debrumyl |
- |
- |
- |
- |
1件: 6 |
365 |
Deferiprone |
Deferiprone |
D07416 |
- |
- |
5件: 2, 6, 120, 122, 233 |
366 |
Deferiprone (ferriprox) |
Deferiprone |
D07416 |
- |
- |
1件: 6 |
367 |
Deferiprone 600 mg delayed release tablet |
Deferiprone |
D07416 |
- |
- |
1件: 6 |
368 |
Desmopressin |
Desmopressin |
D00291, D02235 |
2件: AVPR2, F8 |
4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
5件: 6, 64, 72, 225, 288 |
369 |
Desmopressin acetat |
Desmopressin |
D00291, D02235 |
2件: AVPR2, F8 |
4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
1件: 6 |
370 |
Desmotabs |
- |
- |
- |
- |
1件: 6 |
371 |
Desmotabs® 0,2 mg tabletten |
- |
- |
- |
- |
1件: 6 |
372 |
Desmotabs® 0,2mg tabletten |
- |
- |
- |
- |
1件: 6 |
373 |
Dexdor |
- |
- |
- |
- |
4件: 2, 4, 6, 70 |
374 |
Dexmedetomidina |
Dexmedetomidine |
D00514, D01205 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 6 |
375 |
Dexmedetomidine |
Dexmedetomidine |
D00514, D01205 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
11件: 2, 4, 6, 21, 34, 70, 113, 212, 215, 226, 280 |
376 |
Dexmedetomidine hydrochloride infusion |
Dexmedetomidine |
D00514, D01205 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 6 |
377 |
Dextromethorphan |
Dextromethorphan |
D00848, D03742, D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
9件: 2, 6, 8, 13, 46, 78, 96, 97, 156 |
378 |
Different diets |
- |
- |
- |
- |
1件: 6 |
379 |
Dihydroergotoxine mesylate |
Ergoloid mesylate |
D02268 |
6件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C |
7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 6 |
380 |
Dipivefrin |
Dipivefrin |
D02349 |
9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
381 |
Dipivefrine |
Dipivefrin |
D02349 |
9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
382 |
Dipraglurant |
Dipraglurant |
- |
- |
- |
1件: 6 |
383 |
Ditropan elixir |
Oxybutynin |
D00465, D00722 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 6 |
384 |
Dm-1992 |
- |
- |
- |
- |
1件: 6 |
385 |
Dnl151 high dose |
- |
- |
- |
- |
1件: 6 |
386 |
Dnl151 low dose |
- |
- |
- |
- |
1件: 6 |
387 |
Dnl201 high dose |
- |
- |
- |
- |
1件: 6 |
388 |
Dnl201 low dose |
- |
- |
- |
- |
1件: 6 |
389 |
Dns-7801 (high dose) |
- |
- |
- |
- |
1件: 6 |
390 |
Dns-7801 (low-dose) |
- |
- |
- |
- |
1件: 6 |
391 |
Docosahexaenoic acid |
Doconexent |
- |
- |
- |
7件: 6, 49, 90, 94, 240, 299, 301 |
392 |
Docosahexaenoic acid (dha) |
Doconexent |
- |
- |
- |
3件: 6, 94, 299 |
393 |
Domperidone |
Domperidone |
D01745, D07868 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
5件: 6, 13, 17, 51, 230 |
394 |
Domperidone (drug) |
Domperidone |
D01745, D07868 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
395 |
Dompéridone |
- |
- |
- |
- |
1件: 6 |
396 |
Donepezil |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
9件: 5, 6, 13, 46, 78, 124, 127, 156, 206 |
397 |
Donepezil sandoz |
Donepezil |
D00670, D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 6 |
398 |
Dopamine |
Dopamine |
D00633, D07870 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
3件: 6, 7, 74 |
399 |
Dopamine agent |
Dopamine |
D00633, D07870 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
400 |
Dopamine agonists (pramipexole, ropirinole) |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
401 |
Dopaminergic agonist + apomorphine |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
402 |
Dopaminergic agonists |
- |
- |
- |
- |
1件: 6 |
403 |
Dops |
Droxidopa |
D01277 |
9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 6, 17 |
404 |
Doxepin |
Doxepin |
D00814, D07875 |
3件: HRH1, SLC6A2, SLC6A4 |
5件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle |
1件: 6 |
405 |
Doxepin and zopiclone |
Zopiclone |
D01372 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 6 |
406 |
Dpa-714-pet/mri |
- |
- |
- |
- |
1件: 6 |
407 |
Droxidopa |
Droxidopa |
D01277 |
9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
3件: 5, 6, 17 |
408 |
Duloxetine |
Duloxetine |
D01179, D07880 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
2件: 6, 13 |
409 |
Duloxetine hydrochloride |
Duloxetine |
D01179, D07880 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
1件: 6 |
410 |
Duodopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
411 |
Duodopa intestinal gel |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
412 |
Duodopa ld/cd 20/5 mg/ml |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
413 |
Dynacirc cr (isradipine) |
Isradipine |
D00349 |
4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S |
34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
414 |
E2007 |
- |
- |
- |
- |
2件: 6, 144 |
415 |
Ebixa |
Memantine |
D04905, D08174 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
3件: 2, 6, 13 |
416 |
Ebixa® |
- |
- |
- |
- |
1件: 6 |
417 |
Egcg |
Epigallocatechin gallate |
- |
- |
- |
8件: 6, 13, 17, 28, 85, 113, 206, 299 |
418 |
Elc200 |
- |
- |
- |
- |
1件: 6 |
419 |
Eliprodil |
Eliprodil |
- |
- |
- |
1件: 6 |
420 |
Eltoprazine |
Eltoprazine |
- |
- |
- |
1件: 6 |
421 |
Eltoprazine hcl |
Eltoprazine |
- |
- |
- |
1件: 6 |
422 |
Eltoprazine hydrochloride |
Eltoprazine |
- |
- |
- |
1件: 6 |
423 |
Emd 128130 |
- |
- |
- |
- |
2件: 6, 156 |
424 |
Emd128130 |
- |
- |
- |
- |
1件: 6 |
425 |
Ent-01 |
- |
- |
- |
- |
1件: 6 |
426 |
Entacapon |
- |
- |
- |
- |
1件: 6 |
427 |
Entacapona |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
428 |
Entacapone |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
2件: 6, 17 |
429 |
Entacapone and carbidopa |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
430 |
Epi-589 |
- |
- |
- |
- |
2件: 2, 6 |
431 |
Epi-743 200mg |
- |
- |
- |
- |
1件: 6 |
432 |
Epi-743 400mg |
- |
- |
- |
- |
1件: 6 |
433 |
Er cd-ld |
- |
- |
- |
- |
1件: 6 |
434 |
Er tablet 100 mg azd3241 |
- |
- |
- |
- |
1件: 6 |
435 |
Er tablet 25 mg azd3241 |
- |
- |
- |
- |
1件: 6 |
436 |
Eradication of helcobacter pylori |
- |
- |
- |
- |
1件: 6 |
437 |
Eradication therapy for h.pylori infection |
- |
- |
- |
- |
1件: 6 |
438 |
Eradication therapy for helicobacter pylori |
- |
- |
- |
- |
1件: 6 |
439 |
Erythromycin |
Erythromycin |
D00140, D00851, D01361, D02009, D02184, D02523, D02524, D02525, D04054 |
- |
- |
5件: 6, 36, 164, 228, 291 |
440 |
Erythropoietin |
Erythropoietin |
D03231 |
1件: EPOR |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
8件: 2, 6, 13, 22, 47, 70, 95, 96 |
441 |
Erythropoietin human recombinant (eporh) |
Erythropoietin |
D03231 |
1件: EPOR |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
1件: 6 |
442 |
Escitalopram |
Escitalopram |
D02567, D07704, D07913 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 2, 6, 13 |
443 |
Esomeprazole |
Esomeprazole |
D01984, D04056, D07917, D09339 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
6件: 6, 46, 86, 98, 298, 299 |
444 |
Eszopiclone |
Eszopiclone |
D02624 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
3件: 6, 13, 46 |
445 |
Ethnodyne visio |
- |
- |
- |
- |
1件: 6 |
446 |
Exametazime |
Exametazime |
D01109 |
- |
- |
1件: 6 |
447 |
Exelon |
Rivastigmine |
D02558, D03822 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
2件: 6, 13 |
448 |
Exelon 4.6 mg/24 h transdermal patch |
Rivastigmine |
D02558, D03822 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 6 |
449 |
Exelon 9.5 mg/24 h transdermal patch |
Rivastigmine |
D02558, D03822 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 6 |
450 |
Exelon patch (rivastigmine transdermal system) |
Rivastigmine |
D02558, D03822 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 6 |
451 |
Exenatide |
Exenatide |
D04121 |
1件: GLP1R |
3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
3件: 6, 193, 233 |
452 |
Exenatide 10 micrograms |
Exenatide |
D04121 |
1件: GLP1R |
3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 6 |
453 |
Exenatide 5 micrograms |
Exenatide |
D04121 |
1件: GLP1R |
3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 6 |
454 |
F-18 fpcit |
- |
- |
- |
- |
1件: 6 |
455 |
Famotidine |
Famotidine |
D00318 |
1件: HRH2 |
3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction |
3件: 6, 46, 86 |
456 |
Febuxostat |
Febuxostat |
D01206 |
1件: XDH |
5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
3件: 2, 6, 13 |
457 |
Ferrprox (deferiprone) |
Deferiprone |
D07416 |
- |
- |
1件: 6 |
458 |
Fesoterodine |
Fesoterodine |
D07226 |
2件: CHRM2, CHRM3 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 6 |
459 |
Fetal porcine cells, neurocell-pd |
- |
- |
- |
- |
1件: 6 |
460 |
Filgrastim |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
25件: 2, 6, 13, 25, 26, 28, 34, 35, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 283, 284, 285, 331 |
461 |
Finasteride |
Finasteride |
D00321 |
1件: SRD5A2 |
2件: Prostate cancer, Steroid hormone biosynthesis |
1件: 6 |
462 |
Fipamezole |
Fipamezole |
- |
- |
- |
2件: 6, 17 |
463 |
Fipamezole hydrochloride |
Fipamezole |
- |
- |
- |
2件: 6, 17 |
464 |
Fipamezole hydrochloride 30 mg oral disintegrating tablets |
Fipamezole |
- |
- |
- |
2件: 6, 17 |
465 |
Fipamezole hydrochloride 60 mg oral disintegrating tablets |
Fipamezole |
- |
- |
- |
2件: 6, 17 |
466 |
Fipamezole hydrochloride 90 mg oral disintegrating tablets |
Fipamezole |
- |
- |
- |
2件: 6, 17 |
467 |
Fipamezole odt |
Fipamezole |
- |
- |
- |
1件: 6 |
468 |
Fipamezole odt cohort 2 |
Fipamezole |
- |
- |
- |
1件: 6 |
469 |
Flecainide |
Flecainide |
D00638, D07962 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
1件: 6 |
470 |
Flecainide acetate |
Flecainide |
D00638, D07962 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
1件: 6 |
471 |
Flecainidum |
Flecainide |
D00638, D07962 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
1件: 6 |
472 |
Florbetaben (18f) |
- |
- |
- |
- |
1件: 6 |
473 |
Florbetapir f 18 |
- |
- |
- |
- |
1件: 6 |
474 |
Fludrocortisone |
Fludrocortisone |
D00986, D07967 |
1件: NR3C2 |
1件: Aldosterone-regulated sodium reabsorption |
3件: 6, 17, 81 |
475 |
Flumazenil |
Flumazenil |
D00697 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
5件: 6, 13, 17, 18, 206 |
476 |
Flutemetamol |
Flutemetamol |
- |
- |
- |
5件: 5, 6, 7, 17, 127 |
477 |
Folic acid |
Folic acid |
D00070 |
- |
- |
4件: 6, 46, 49, 84 |
478 |
Folic acid, vitamin b6, vitamin b12 |
Folic acid |
D00070 |
- |
- |
1件: 6 |
479 |
Foliglurax |
Foliglurax |
- |
- |
- |
1件: 6 |
480 |
Fpf1100nw |
- |
- |
- |
- |
1件: 6 |
481 |
Fpfs-1169 |
- |
- |
- |
- |
1件: 6 |
482 |
Fursultiamine |
Fursultiamine |
D03319 |
- |
- |
1件: 6 |
483 |
G-csf |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
12件: 6, 13, 16, 49, 51, 60, 65, 85, 96, 284, 285, 331 |
484 |
Gabapentin |
Gabapentin |
D00332 |
5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 |
9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), GABAergic synapse, Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
5件: 6, 13, 19, 70, 298 |
485 |
Gabapentina |
Gabapentin |
D00332 |
5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 |
9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), GABAergic synapse, Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
1件: 6 |
486 |
Gabapentina kern pharma |
Gabapentin |
D00332 |
5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 |
9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), GABAergic synapse, Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
1件: 6 |
487 |
Galantamine |
Galantamine |
D02173, D04292 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
2件: 6, 127 |
488 |
Ganoderma |
- |
- |
- |
- |
1件: 6 |
489 |
Ghrelin |
Lenomorelin |
- |
- |
- |
3件: 6, 78, 299 |
490 |
Ginkgo |
Ginkgo biloba |
- |
- |
- |
3件: 6, 13, 90 |
491 |
Glial cell line-derived neurotrophic factor |
- |
- |
- |
- |
1件: 6 |
492 |
Glial cell line-derived neurotrophic factor (gdnf) |
- |
- |
- |
- |
1件: 6 |
493 |
Glucose |
D-glucose |
D00009 |
- |
- |
3件: 6, 13, 299 |
494 |
Glutathione |
Glutathione |
D00014, D00031 |
- |
- |
2件: 6, 299 |
495 |
Glycerol |
Glycerin |
D00028 |
- |
- |
4件: 6, 13, 316, 317 |
496 |
Glycerol phenylbutyrate |
Glycerol phenylbutyrate |
D10127 |
- |
- |
1件: 6 |
497 |
Glycopyrrolate |
Glycopyrronium |
D00540, D10938 |
1件: CHRM3 |
9件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction |
1件: 6 |
498 |
Gm1 ganglioside |
- |
- |
- |
- |
1件: 6 |
499 |
Gm608 |
- |
- |
- |
- |
1件: 6 |
500 |
Gold |
Gold |
- |
- |
- |
5件: 2, 6, 13, 46, 171 |
501 |
Gold nanocrystals |
Gold |
- |
- |
- |
3件: 2, 6, 13 |
502 |
Gpi 1485 |
- |
- |
- |
- |
1件: 6 |
503 |
Grapefruit |
Grapefruit |
- |
- |
- |
5件: 6, 46, 50, 83, 97 |
504 |
Green tea |
Green tea leaf |
D06903 |
- |
- |
5件: 6, 17, 28, 46, 96 |
505 |
Green tea polyphenols (egcg/ecg) |
Green tea leaf |
D06903 |
- |
- |
1件: 6 |
506 |
Grf6021 |
- |
- |
- |
- |
1件: 6 |
507 |
Group ad anti-pd + antidepressant |
- |
- |
- |
- |
1件: 6 |
508 |
Group r rasagiline |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
509 |
Group r+ad rasagiline + antidepressant |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
510 |
Gsk962040 |
- |
- |
- |
- |
1件: 6 |
511 |
Gsk962040 (25 mg tablet) |
- |
- |
- |
- |
1件: 6 |
512 |
Gz/sar402671 |
- |
- |
- |
- |
2件: 6, 19 |
513 |
Hb-admsc |
- |
- |
- |
- |
2件: 6, 46 |
514 |
Helicobacter pylori eradication therapy |
- |
- |
- |
- |
1件: 6 |
515 |
Heptaminol |
Heptaminol |
D07158 |
- |
- |
1件: 6 |
516 |
Heptaminol hydrochloride |
Heptaminol |
D07158 |
- |
- |
1件: 6 |
517 |
Herbal medicinal mixture (roucongrong, heshouwu etc.) |
Reynoutria multiflora root |
- |
- |
- |
1件: 6 |
518 |
Heshouwu |
Reynoutria multiflora root |
- |
- |
- |
1件: 6 |
519 |
Hf0220 |
- |
- |
- |
- |
1件: 6 |
520 |
High dose affitope® pd03a + adjuvant |
- |
- |
- |
- |
1件: 6 |
521 |
High dose anavex2-73 |
- |
- |
- |
- |
1件: 6 |
522 |
High protein. t-diet plus range |
- |
- |
- |
- |
1件: 6 |
523 |
Hp-3000 (ropinirole hydrochloride patch) |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
524 |
Hp-3000 placebo |
- |
- |
- |
- |
1件: 6 |
525 |
Hp-3000(ropinirole hydrochloride patch) |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
526 |
Human neural stem cell |
- |
- |
- |
- |
1件: 6 |
527 |
Human stem cells |
- |
- |
- |
- |
1件: 6 |
528 |
Hydrocortisone |
Hydrocortisone |
D00088 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
8件: 6, 53, 75, 78, 81, 83, 97, 299 |
529 |
Hydrocortisone cream |
Hydrocortisone |
D00088 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 6 |
530 |
Hydrocortisone cream 1% |
Hydrocortisone |
D00088 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 6 |
531 |
Hydrocortisone cream 10mg/g fna fagron |
Hydrocortisone |
D00088 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 6 |
532 |
Hydrogen |
Hydrogen |
- |
- |
- |
5件: 5, 6, 17, 97, 226 |
533 |
I 123 |
Iodide i-123 |
- |
- |
- |
1件: 6 |
534 |
I-123 |
Iodide i-123 |
- |
- |
- |
2件: 2, 6 |
535 |
I-123-5-ia85380 |
Iodide i-123 |
- |
- |
- |
1件: 6 |
536 |
Iberogast |
- |
- |
- |
- |
1件: 6 |
537 |
Idebenone |
Idebenone |
D01750 |
- |
- |
4件: 6, 13, 113, 302 |
538 |
Immediate release carbidopa/levodopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
539 |
Immediate release carbidopa/levodopa 25/100 mg |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
540 |
Impact |
Topramezone |
- |
- |
- |
7件: 6, 13, 46, 50, 96, 97, 299 |
541 |
Incobotulinum toxin a |
- |
- |
- |
- |
2件: 2, 6 |
542 |
Incobotulinumtoxina |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
1件: 6 |
543 |
Infudopa i.v. |
- |
- |
- |
- |
1件: 6 |
544 |
Infudopa s.c. |
- |
- |
- |
- |
1件: 6 |
545 |
Infusions of young plasma |
- |
- |
- |
- |
1件: 6 |
546 |
Inhaled vr040 |
- |
- |
- |
- |
1件: 6 |
547 |
Injection of apomorphine |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
548 |
Injection of normal saline |
- |
- |
- |
- |
1件: 6 |
549 |
Injection of umbilical cord derived mscs |
- |
- |
- |
- |
1件: 6 |
550 |
Inosine |
Inosine |
D00054 |
- |
- |
4件: 2, 6, 13, 17 |
551 |
Intracerebral microinjections |
- |
- |
- |
- |
1件: 6 |
552 |
Intranasal glutathione - (in)gsh |
Glutathione |
D00014, D00031 |
- |
- |
1件: 6 |
553 |
Intranasal insulin |
- |
- |
- |
- |
2件: 6, 17 |
554 |
Intravenous and oral n—acetyl cysteine |
L-cysteine |
D00026, D02326 |
- |
- |
1件: 6 |
555 |
Intravenous infusion |
- |
- |
- |
- |
1件: 6 |
556 |
Intravenous levodopa |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
557 |
Intravesical injection of botulinum a toxin |
- |
- |
- |
- |
2件: 6, 17 |
558 |
Ioflupane (123i) |
Ioflupane i-123 |
D10014 |
- |
- |
1件: 6 |
559 |
Ioflupane 123i (datscan®) |
- |
- |
- |
- |
1件: 6 |
560 |
Ioflupane [123 i] |
Ioflupane i-123 |
D10014 |
- |
- |
1件: 6 |
561 |
Ioflupane i 123 |
Ioflupane i-123 |
D10014 |
- |
- |
1件: 6 |
562 |
Ipratropium |
Ipratropium |
D02212 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
2件: 6, 86 |
563 |
Ipratropium bromide (drug) |
Ipratropium |
D02212 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 6 |
564 |
Iproniazid |
Iproniazid |
D02579 |
2件: MAOA, MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
565 |
Ips-nsc cells |
- |
- |
- |
- |
1件: 6 |
566 |
Ipt803 |
- |
- |
- |
- |
1件: 6 |
567 |
Ipx054 100 mg |
- |
- |
- |
- |
1件: 6 |
568 |
Ipx054 150 mg |
- |
- |
- |
- |
1件: 6 |
569 |
Ipx054 200 mg |
- |
- |
- |
- |
1件: 6 |
570 |
Ipx054 250 mg |
- |
- |
- |
- |
1件: 6 |
571 |
Ipx054 300 mg |
- |
- |
- |
- |
1件: 6 |
572 |
Ipx066 |
- |
- |
- |
- |
1件: 6 |
573 |
Ipx066 145 mg |
- |
- |
- |
- |
1件: 6 |
574 |
Ipx066 145 mg ld |
- |
- |
- |
- |
1件: 6 |
575 |
Ipx066 195 mg |
- |
- |
- |
- |
1件: 6 |
576 |
Ipx066 195 mg ld |
- |
- |
- |
- |
1件: 6 |
577 |
Ipx066 245 mg |
- |
- |
- |
- |
1件: 6 |
578 |
Ipx066 245 mg ld |
- |
- |
- |
- |
1件: 6 |
579 |
Ipx066 95 mg |
- |
- |
- |
- |
1件: 6 |
580 |
Ipx066 95 mg ld |
- |
- |
- |
- |
1件: 6 |
581 |
Ipx066-145 |
- |
- |
- |
- |
1件: 6 |
582 |
Ipx066-195 |
- |
- |
- |
- |
1件: 6 |
583 |
Ipx066-245 |
- |
- |
- |
- |
1件: 6 |
584 |
Ipx066-95 |
- |
- |
- |
- |
1件: 6 |
585 |
Ipx203 140 mg |
- |
- |
- |
- |
1件: 6 |
586 |
Ipx203 180 mg |
- |
- |
- |
- |
1件: 6 |
587 |
Ipx203 210 mg |
- |
- |
- |
- |
1件: 6 |
588 |
Ipx203 270 mg |
- |
- |
- |
- |
1件: 6 |
589 |
Ipx203 280 mg |
- |
- |
- |
- |
1件: 6 |
590 |
Ipx203 350 mg |
- |
- |
- |
- |
1件: 6 |
591 |
Ipx203 er cd-ld |
- |
- |
- |
- |
1件: 6 |
592 |
Ir cd-ld |
- |
- |
- |
- |
1件: 6 |
593 |
Irl752 |
- |
- |
- |
- |
1件: 6 |
594 |
Irl790 |
- |
- |
- |
- |
1件: 6 |
595 |
Irx4204 |
- |
- |
- |
- |
1件: 6 |
596 |
Isc-hpnsc |
- |
- |
- |
- |
1件: 6 |
597 |
Isicom |
- |
- |
- |
- |
1件: 6 |
598 |
Isoflurane |
Isoflurane |
D00545 |
- |
- |
1件: 6 |
599 |
Isradipine |
Isradipine |
D00349 |
4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S |
34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
600 |
Isradipine cr 10mg |
Isradipine |
D00349 |
4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S |
34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
601 |
Isradipine cr 20mg |
Isradipine |
D00349 |
4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S |
34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
602 |
Isradipine cr 5mg |
Isradipine |
D00349 |
4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S |
34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
603 |
Istradefylline |
Istradefylline |
D04641 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
604 |
Istradefylline ( kw-6002) |
Istradefylline |
D04641 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
605 |
Istradefylline (kw-6002) |
Istradefylline |
D04641 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
606 |
Istradefylline 20 mg |
Istradefylline |
D04641 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
607 |
Istradefylline 20 mg or 40 mg |
Istradefylline |
D04641 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
608 |
Istradefylline 40 mg |
Istradefylline |
D04641 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
609 |
Iti-214 |
- |
- |
- |
- |
1件: 6 |
610 |
Iv apomorphine |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
611 |
Iv levodopa |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
612 |
Jm-010 |
- |
- |
- |
- |
1件: 6 |
613 |
Jm-010 a group |
- |
- |
- |
- |
1件: 6 |
614 |
Jm-010 b group |
- |
- |
- |
- |
1件: 6 |
615 |
Jnj-31001074 |
- |
- |
- |
- |
1件: 6 |
616 |
Jp 1730 |
- |
- |
- |
- |
1件: 6 |
617 |
Jp-1730/f01 |
- |
- |
- |
- |
2件: 6, 17 |
618 |
Jp-1730/f02 |
- |
- |
- |
- |
2件: 6, 17 |
619 |
Jp-1730/f03 |
- |
- |
- |
- |
2件: 6, 17 |
620 |
Jzp-110 |
- |
- |
- |
- |
1件: 6 |
621 |
K0706 |
- |
- |
- |
- |
1件: 6 |
622 |
Kdt-3594 |
- |
- |
- |
- |
1件: 6 |
623 |
Ketone ester drink |
- |
- |
- |
- |
1件: 6 |
624 |
Kinoquinone (proposed) |
- |
- |
- |
- |
1件: 6 |
625 |
Km-819 |
- |
- |
- |
- |
1件: 6 |
626 |
Kw-6002 |
- |
- |
- |
- |
1件: 6 |
627 |
Kw-6002 (istradefylline) |
Istradefylline |
D04641 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
628 |
Kw-6356 |
- |
- |
- |
- |
1件: 6 |
629 |
Kw-6356 high dose |
- |
- |
- |
- |
1件: 6 |
630 |
Kw-6356 low dose |
- |
- |
- |
- |
1件: 6 |
631 |
Kw-6356 middle dose |
- |
- |
- |
- |
1件: 6 |
632 |
Kw-6356 x dose |
- |
- |
- |
- |
1件: 6 |
633 |
Kw-6356 y dose |
- |
- |
- |
- |
1件: 6 |
634 |
Kw-6500 |
- |
- |
- |
- |
1件: 6 |
635 |
L-123 ioflupane |
- |
- |
- |
- |
1件: 6 |
636 |
L-dopa |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
637 |
L-dopa/ modopar |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
638 |
L-dops |
Droxidopa |
D01277 |
9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
639 |
L-methylfolate |
Levomefolic acid |
D09353 |
- |
- |
1件: 6 |
640 |
L-tyrosine |
Tyrosine |
D00022 |
- |
- |
2件: 6, 111 |
641 |
Lactobacillus plantarum |
Lactobacillus plantarum |
- |
- |
- |
2件: 6, 156 |
642 |
Lactobacillus plantarum ps128 |
Lactobacillus plantarum |
- |
- |
- |
1件: 6 |
643 |
Lactose |
Lactose |
D00046, D03226 |
- |
- |
6件: 2, 6, 13, 97, 228, 310 |
644 |
Lcig |
- |
- |
- |
- |
1件: 6 |
645 |
Lcig (duodopa) |
- |
- |
- |
- |
1件: 6 |
646 |
Ld / be |
- |
- |
- |
- |
1件: 6 |
647 |
Ld+ddci |
- |
- |
- |
- |
1件: 6 |
648 |
Ld-ddci |
- |
- |
- |
- |
1件: 6 |
649 |
Ld/cd |
- |
- |
- |
- |
1件: 6 |
650 |
Leptin |
Leptin |
- |
- |
- |
2件: 6, 265 |
651 |
Leucine |
L-leucine |
D00030 |
- |
- |
7件: 5, 6, 7, 127, 283, 284, 299 |
652 |
Levetiracetam |
Levetiracetam |
D00709 |
1件: SV2A |
1件: ECM-receptor interaction |
4件: 2, 4, 6, 13 |
653 |
Levodopa |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
7件: 2, 4, 6, 17, 90, 164, 201 |
654 |
Levodopa (delivered intravenously) |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
655 |
Levodopa (drug), intraduodenal administration |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
656 |
Levodopa (l-dopa) |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
657 |
Levodopa (l-dopa) + standard care |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
658 |
Levodopa / benserazid |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
659 |
Levodopa / benserazide 200 + 50 mg |
Benserazide |
D03082 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
660 |
Levodopa 100 mg / benserazide 25 mg |
Benserazide |
D03082 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
661 |
Levodopa 100 mg a cap |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
662 |
Levodopa 125 mg a cap |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
663 |
Levodopa 150 mg a cap |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
664 |
Levodopa 25mg/100mg |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
665 |
Levodopa 75 mg a cap |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
666 |
Levodopa acute challenge |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
667 |
Levodopa and carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
668 |
Levodopa and carbidopa sc solution |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
669 |
Levodopa and carbidopa solution for sc administration |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
670 |
Levodopa and decarboxylase inhibitor |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
671 |
Levodopa and domperidone |
Domperidone |
D01745, D07868 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
672 |
Levodopa benserazide madopar |
Benserazide |
D03082 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
673 |
Levodopa benserazide teva italia |
Benserazide |
D03082 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
674 |
Levodopa carbidopa (lc) oral encapsulated immediate release (ir) tablets |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
675 |
Levodopa carbidopa intestinal gel (lcig) |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
676 |
Levodopa cr (controlled release) |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
677 |
Levodopa cyclops |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
678 |
Levodopa dc.it fu |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
679 |
Levodopa dispersible |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
680 |
Levodopa infusion |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
681 |
Levodopa mr |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
682 |
Levodopa powder for inhalation |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
683 |
Levodopa, carbidopa, entacapone |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
684 |
Levodopa, carbidopa, odm-104 |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
685 |
Levodopa, decarboxylase inhibitor and comt inhibitor |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
686 |
Levodopa-carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
2件: 6, 90 |
687 |
Levodopa-carbidopa (lc) oral encapsulated immediate release (ir) tablets |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
688 |
Levodopa-carbidopa immediate release (lc-ir) tablets |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
689 |
Levodopa-carbidopa intestinal gel |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
690 |
Levodopa-carbidopa multilayer extended release tablet |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
691 |
Levodopa-carbidopa xl tablet (m) |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
692 |
Levodopa-carbidopa-entacapone |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
693 |
Levodopa/benserazide |
Benserazide |
D03082 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
694 |
Levodopa/benserazide 100/25 mg |
Benserazide |
D03082 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
695 |
Levodopa/benzeraside |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
696 |
Levodopa/benzerazide |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
697 |
Levodopa/carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
2件: 6, 164 |
698 |
Levodopa/carbidopa (sinemet) |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
699 |
Levodopa/carbidopa 100/25 |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
700 |
Levodopa/carbidopa hydrate |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
701 |
Levodopa/carbidopa solution |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
702 |
Levodopa/carbidopa(200mg/50mg) |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
703 |
Levodopa/carbidopa/entacapone |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
704 |
Levodopa/ddci |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
705 |
Liatermin |
Liatermin |
D04727 |
- |
- |
1件: 6 |
706 |
Liatermin (r-methugdnf) |
Liatermin |
D04727 |
- |
- |
1件: 6 |
707 |
Lidocaine |
Lidocaine |
D00358, D02086, D08127 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
8件: 6, 13, 46, 86, 168, 226, 231, 256 |
708 |
Lingzhi (ganoderma) |
- |
- |
- |
- |
1件: 6 |
709 |
Liraglutide |
Liraglutide |
D06404 |
1件: GLP1R |
3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
3件: 6, 75, 193 |
710 |
Lisparin |
- |
- |
- |
- |
1件: 6 |
711 |
Lisuride |
Lisuride |
D01462, D08132 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
2件: 6, 86 |
712 |
Lisuride hydrogenmaleate |
Lisuride |
D01462, D08132 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
713 |
Lisuride transdermal system |
Lisuride |
D01462, D08132 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
714 |
Lisuride tts 10cm² |
Lisuride |
D01462, D08132 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
715 |
Lisuride tts 20cm² |
Lisuride |
D01462, D08132 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
716 |
Lixisenatide |
Lixisenatide |
D09729 |
1件: GLP1R |
3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 6 |
717 |
Local anesthesia (lidocaine hydrochloride) |
Lidocaine |
D00358, D02086, D08127 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
1件: 6 |
718 |
Lodalès® |
- |
- |
- |
- |
1件: 6 |
719 |
Lodosyn® |
- |
- |
- |
- |
1件: 6 |
720 |
Lovastatin |
Lovastatin |
D00359 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
10件: 6, 34, 46, 79, 156, 160, 195, 206, 263, 310 |
721 |
Low dose affitope® pd03a + adjuvant |
- |
- |
- |
- |
1件: 6 |
722 |
Lu 00-800 |
- |
- |
- |
- |
1件: 6 |
723 |
Lu ae04621 |
- |
- |
- |
- |
1件: 6 |
724 |
Lu af82422 |
- |
- |
- |
- |
1件: 6 |
725 |
Lubiprostone |
Lubiprostone |
D04790 |
1件: CLCN2 |
1件: Mineral absorption |
4件: 6, 13, 290, 299 |
726 |
Ly03003 |
- |
- |
- |
- |
1件: 6 |
727 |
Ly300164 |
- |
- |
- |
- |
1件: 6 |
728 |
Ly3154207 |
- |
- |
- |
- |
1件: 6 |
729 |
Madopar |
- |
- |
- |
- |
1件: 6 |
730 |
Madopar 125 mg, orodispersible tablet |
- |
- |
- |
- |
1件: 6 |
731 |
Madopar 200+50 mg |
- |
- |
- |
- |
1件: 6 |
732 |
Madopar lt |
- |
- |
- |
- |
1件: 6 |
733 |
Madopar® 125 |
- |
- |
- |
- |
1件: 6 |
734 |
Madopar® 250 |
- |
- |
- |
- |
1件: 6 |
735 |
Madopar® hbs |
- |
- |
- |
- |
1件: 6 |
736 |
Madopar® hbs 125 |
- |
- |
- |
- |
1件: 6 |
737 |
Magnesium |
Magnesium |
- |
- |
- |
15件: 6, 11, 13, 46, 64, 93, 97, 166, 225, 235, 284, 291, 296, 297, 298 |
738 |
Magnesium oxide |
Magnesium oxide |
D01167 |
- |
- |
3件: 6, 166, 291 |
739 |
Maltodextrin |
Maltodextrin |
D02329 |
- |
- |
4件: 6, 13, 96, 97 |
740 |
Mannitol |
Mannitol |
D00062 |
- |
- |
3件: 6, 96, 299 |
741 |
Mantadix |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
742 |
Mars |
- |
- |
- |
- |
1件: 6 |
743 |
Masitinib |
Masitinib |
D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
6件: 2, 5, 6, 13, 46, 96 |
744 |
Masitinib mesylate |
Masitinib |
D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
6件: 2, 5, 6, 13, 46, 96 |
745 |
Me2125 |
- |
- |
- |
- |
1件: 6 |
746 |
Medi1341 |
- |
- |
- |
- |
1件: 6 |
747 |
Melatonin |
Melatonin |
D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
8件: 6, 13, 46, 49, 90, 97, 144, 202 |
748 |
Melatonin pr |
Melatonin |
D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
1件: 6 |
749 |
Melatonin(circadin®) |
Melatonin |
D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
1件: 6 |
750 |
Melevodopa |
Melevodopa |
D07304 |
- |
- |
1件: 6 |
751 |
Melevodopa and decarboxylase inhibitor |
Melevodopa |
D07304 |
- |
- |
1件: 6 |
752 |
Melperon |
- |
- |
- |
- |
1件: 6 |
753 |
Melperone |
Melperone |
D07309 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
754 |
Melperone hcl |
Melperone |
D07309 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
755 |
Memantin |
Memantine |
D04905, D08174 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
756 |
Memantin orion |
Memantine |
D04905, D08174 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
757 |
Memantine |
Memantine |
D04905, D08174 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
7件: 2, 6, 8, 13, 49, 127, 205 |
758 |
Memantine hydrochloride |
Memantine |
D04905, D08174 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
3件: 2, 6, 127 |
759 |
Mesencephalic neuronal precursor cells |
- |
- |
- |
- |
1件: 6 |
760 |
Mesenchymal stem cells |
- |
- |
- |
- |
11件: 2, 6, 13, 20, 49, 51, 60, 96, 222, 274, 299 |
761 |
Mestinon |
Pyridostigmine |
D00487 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
3件: 3, 6, 11 |
762 |
Metformin |
Metformin |
D00944, D04966 |
2件: PRKAA1, PRKAA2 |
19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
16件: 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285 |
763 |
Methylphenidate |
Methylphenidate |
D01296, D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
7件: 6, 13, 34, 84, 113, 179, 206 |
764 |
Methylphenidate (mpd) |
Methylphenidate |
D01296, D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
1件: 6 |
765 |
Methylphenidate hydrochloride |
Methylphenidate |
D01296, D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
2件: 6, 13 |
766 |
Mid dose anavex2-73 |
- |
- |
- |
- |
1件: 6 |
767 |
Midazolam |
Midazolam |
D00550, D00696, D05028 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
10件: 2, 3, 6, 13, 46, 70, 96, 97, 231, 298 |
768 |
Midodrine |
Midodrine |
D01307, D08220 |
3件: ADRA1A, ADRA1B, ADRA1D |
7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
3件: 6, 17, 58 |
769 |
Minocycline |
Minocycline |
D00850, D05045 |
- |
- |
13件: 2, 6, 8, 13, 46, 85, 90, 94, 162, 201, 206, 280, 299 |
770 |
Minodronic acid |
Minodronic acid |
- |
- |
- |
4件: 6, 46, 93, 95 |
771 |
Mirabegron |
Mirabegron |
D09535 |
1件: ADRB3 |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cGMP-PKG signaling pathway |
3件: 6, 13, 226 |
772 |
Mirapex |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
773 |
Mirapex (pramipexole) |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
774 |
Mirapex er |
- |
- |
- |
- |
1件: 6 |
775 |
Mirapex la |
- |
- |
- |
- |
1件: 6 |
776 |
Mirapexin |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
777 |
Mirapexin extended release various strengths |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
778 |
Mirapexin*30cpr 0,7mg |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
779 |
Mitoq |
- |
- |
- |
- |
1件: 6 |
780 |
Mk0657 |
- |
- |
- |
- |
1件: 6 |
781 |
Moclobemide |
Moclobemide |
D02561 |
1件: MAOA |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
782 |
Modafinil |
Modafinil |
D01832 |
- |
- |
4件: 6, 13, 49, 93 |
783 |
Modafinil 50mg |
Modafinil |
D01832 |
- |
- |
1件: 6 |
784 |
Modiodal |
- |
- |
- |
- |
1件: 6 |
785 |
Modopar |
- |
- |
- |
- |
1件: 6 |
786 |
Monoamine oxidase b inhibitors |
- |
- |
- |
- |
1件: 6 |
787 |
Motilium |
- |
- |
- |
- |
2件: 6, 230 |
788 |
Moxifloxacin |
Moxifloxacin |
D00874, D08237 |
- |
- |
8件: 2, 6, 46, 49, 85, 86, 240, 299 |
789 |
Moxifloxacin infusion |
Moxifloxacin |
D00874, D08237 |
- |
- |
1件: 6 |
790 |
Moxifloxacina cloridrato |
- |
- |
- |
- |
1件: 6 |
791 |
Muscimol |
Muscimol |
- |
- |
- |
1件: 6 |
792 |
Mémantine |
- |
- |
- |
- |
1件: 6 |
793 |
N-0923 |
- |
- |
- |
- |
1件: 6 |
794 |
N-acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
10件: 6, 13, 19, 20, 49, 58, 85, 111, 164, 299 |
795 |
N-acetylcysteine capsule |
Acetylcysteine |
D00221 |
- |
- |
1件: 6 |
796 |
N.a. |
- |
- |
- |
- |
8件: 3, 6, 8, 13, 46, 97, 240, 256 |
797 |
N04bd02 |
- |
- |
- |
- |
1件: 6 |
798 |
Nabilone |
Nabilone |
D05099 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
2件: 6, 13 |
799 |
Nabilone 0.25 mg |
Nabilone |
D05099 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
1件: 6 |
800 |
Nacom |
- |
- |
- |
- |
1件: 6 |
801 |
Nacom 100 |
- |
- |
- |
- |
1件: 6 |
802 |
Nacom levodopa+cardidopa |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
803 |
Nalmefene |
Nalmefene |
D05111 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
804 |
Naloxone |
Naloxone |
D01340, D08249 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
2件: 6, 226 |
805 |
Naltrexone |
Naltrexone |
D02095, D05113 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
806 |
Nardil |
Phenelzine |
D00505, D08349 |
2件: MAOA, MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
807 |
Nbtx-001 |
- |
- |
- |
- |
1件: 6 |
808 |
Nd0611 |
- |
- |
- |
- |
1件: 6 |
809 |
Nd0612 |
- |
- |
- |
- |
1件: 6 |
810 |
Nd0612 (levodopa/carbidopa solution) |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
811 |
Nd1421 |
- |
- |
- |
- |
1件: 6 |
812 |
Nd1587 |
- |
- |
- |
- |
1件: 6 |
813 |
Nd1589 |
- |
- |
- |
- |
1件: 6 |
814 |
Nd1590 |
- |
- |
- |
- |
1件: 6 |
815 |
Nd1702 |
- |
- |
- |
- |
1件: 6 |
816 |
Nebicapone |
Nebicapone |
- |
- |
- |
1件: 6 |
817 |
Nelotanserin |
Nelotanserin |
D09645 |
1件: HTR2A |
5件: Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse |
1件: 6 |
818 |
Neridronic acid |
Neridronic acid |
- |
- |
- |
1件: 6 |
819 |
Nerixia*im ev 1f 25mg |
- |
- |
- |
- |
1件: 6 |
820 |
Neu-120 |
- |
- |
- |
- |
1件: 6 |
821 |
Neupro |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
822 |
Neupro 2 mg/24 h transdermal patch |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
823 |
Neupro 2mg/24 h transdermal patch |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
824 |
Neupro 2mg/24h transdermal patch |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
825 |
Neupro 4 mg/24 h transdermal patch |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
826 |
Neupro 4mg/24 h transdermal patch |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
827 |
Neupro 4mg/24h transdermal patch |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
828 |
Neupro 4mg/24hr transdermal patch |
- |
- |
- |
- |
1件: 6 |
829 |
Neupro 6 mg/24 h transdermal patch |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
830 |
Neupro 6mg/24 h transdermal patch |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
831 |
Neupro 6mg/24h transdermal patch |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
832 |
Neupro 8 mg/24 h transdermal patch |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
833 |
Neupro 8mg/24h transdermal patch |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
834 |
Neupro*28cer 2mg/24h |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
835 |
Neupro*28cer 4mg/24h |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
836 |
Neupro*28cer 6mg/24h |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
837 |
Neupro*28cer 8mg/24h |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
838 |
Neupro*7cer 4mg/24h |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
839 |
Neupro*7cer 6mg/24h |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
840 |
Neupro*7cer 8mg/24h |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
841 |
Neupro® |
- |
- |
- |
- |
1件: 6 |
842 |
Neuraceq |
- |
- |
- |
- |
1件: 6 |
843 |
Neurobloc |
- |
- |
- |
- |
1件: 6 |
844 |
Neuroepo |
- |
- |
- |
- |
1件: 6 |
845 |
Neurohormonal mechanisms |
- |
- |
- |
- |
2件: 6, 127 |
846 |
Neurpro |
- |
- |
- |
- |
1件: 6 |
847 |
Niacin |
Niacin |
D00049 |
- |
- |
3件: 6, 78, 265 |
848 |
Niacinamide |
Nicotinamide |
D00036 |
- |
- |
4件: 5, 6, 13, 67 |
849 |
Nicorette 10mg/ 16 h |
Nicotine |
D03365, D05156, D05157 |
16件: CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG |
5件: Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction |
1件: 6 |
850 |
Nicorette 15 mg/ 16 h |
Nicotine |
D03365, D05156, D05157 |
16件: CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG |
5件: Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction |
1件: 6 |
851 |
Nicorette 5 mg/ 16 h |
Nicotine |
D03365, D05156, D05157 |
16件: CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG |
5件: Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction |
1件: 6 |
852 |
Nicotinamide |
Nicotinamide |
D00036 |
- |
- |
3件: 6, 49, 162 |
853 |
Nicotinamide riboside |
Nicotinamide riboside |
- |
- |
- |
1件: 6 |
854 |
Nicotine |
Nicotine |
D03365, D05156, D05157 |
16件: CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG |
5件: Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction |
2件: 6, 84 |
855 |
Nicotine gum |
Nicotine |
D03365, D05156, D05157 |
16件: CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG |
5件: Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction |
1件: 6 |
856 |
Nicotine nasal spray 10 mg/ml (0.5 mg/spray) |
Nicotine |
D03365, D05156, D05157 |
16件: CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG |
5件: Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction |
1件: 6 |
857 |
Nicotine patch |
Nicotine |
D03365, D05156, D05157 |
16件: CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG |
5件: Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction |
2件: 6, 84 |
858 |
Nicotine transdermal patch |
Nicotine |
D03365, D05156, D05157 |
16件: CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG |
5件: Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction |
1件: 6 |
859 |
Nicotinell |
- |
- |
- |
- |
1件: 6 |
860 |
Nicotinell 17,5 mg/24-stunden-pflaster |
- |
- |
- |
- |
1件: 6 |
861 |
Nicotinell 35 mg/24-stunden-pflaster |
- |
- |
- |
- |
1件: 6 |
862 |
Nilotinib |
Nilotinib |
D08953 |
4件: ABL1, KIT, PDGFRA, PDGFRB |
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
5件: 6, 8, 34, 51, 86 |
863 |
Nilotinib 150mg oral capsule [tasigna] |
Nilotinib |
D08953 |
4件: ABL1, KIT, PDGFRA, PDGFRB |
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
1件: 6 |
864 |
Nilotinib 300mg oral capsule [tasigna] |
Nilotinib |
D08953 |
4件: ABL1, KIT, PDGFRA, PDGFRB |
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
1件: 6 |
865 |
Nitrogen |
Nitrogen |
D00083 |
- |
- |
5件: 5, 6, 17, 211, 299 |
866 |
Nly01 |
- |
- |
- |
- |
1件: 6 |
867 |
Nmda |
Ketamine |
D00711, D08098 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
868 |
Normal saline |
- |
- |
- |
- |
14件: 6, 17, 22, 36, 46, 49, 60, 94, 96, 211, 226, 276, 296, 299 |
869 |
Northera |
Droxidopa |
D01277 |
9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
870 |
Nortriptyline |
Nortriptyline |
D00816, D08288 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
2件: 6, 226 |
871 |
Npc transplantation |
- |
- |
- |
- |
1件: 6 |
872 |
Nr2b nmda antagonist cp-101,606 (traxoprodil) |
Ketamine |
D00711, D08098 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
873 |
Ns 2330 |
- |
- |
- |
- |
1件: 6 |
874 |
Ns2330 |
- |
- |
- |
- |
1件: 6 |
875 |
Nt 101 |
- |
- |
- |
- |
4件: 5, 6, 7, 17 |
876 |
Ntcell implantation |
- |
- |
- |
- |
1件: 6 |
877 |
Null |
- |
- |
- |
- |
17件: 6, 13, 14, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271 |
878 |
Nw-1015 |
- |
- |
- |
- |
1件: 6 |
879 |
Nw-1015e, emd 1195686, msc2191632b |
- |
- |
- |
- |
1件: 6 |
880 |
Nyx-458 |
- |
- |
- |
- |
1件: 6 |
881 |
Oc oral solution treatment a |
- |
- |
- |
- |
1件: 6 |
882 |
Oc oral solution treatment b |
- |
- |
- |
- |
1件: 6 |
883 |
Oc oral solution treatment c |
- |
- |
- |
- |
1件: 6 |
884 |
Oc oral solution treatment d |
- |
- |
- |
- |
1件: 6 |
885 |
Odm-101 |
- |
- |
- |
- |
1件: 6 |
886 |
Odm-101 105mg carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
887 |
Odm-101 65mg carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
888 |
Odm-104 |
- |
- |
- |
- |
1件: 6 |
889 |
Omeprazole |
Omeprazole |
D00455, D01207, D05259, D05261 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
15件: 6, 8, 13, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
890 |
Onabotulinumtoxin a injection |
- |
- |
- |
- |
1件: 6 |
891 |
Onabotulinumtoxina |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
3件: 6, 13, 226 |
892 |
Ongentys |
Opicapone |
D10825 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
893 |
Ono-2160/cd |
- |
- |
- |
- |
1件: 6 |
894 |
Ono-2370 |
- |
- |
- |
- |
1件: 6 |
895 |
Ono-2506po |
- |
- |
- |
- |
2件: 2, 6 |
896 |
Opicapone |
Opicapone |
D10825 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
897 |
Opicapone (opc) |
Opicapone |
D10825 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
898 |
Optimal drug therapy |
- |
- |
- |
- |
1件: 6 |
899 |
Optimized antiparkinsonian treatment |
- |
- |
- |
- |
1件: 6 |
900 |
Oral escitalopram |
Escitalopram |
D02567, D07704, D07913 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
1件: 6 |
901 |
Oral levodopa and carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
902 |
Oral levodopa/carbidopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
903 |
Orally disintegrating selegiline (zelapar) |
Selegiline |
D00785, D03731 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
904 |
Osu 6162 similar to (-)-osu 6162 |
- |
- |
- |
- |
1件: 6 |
905 |
Osu6162 similar to (-)-osu 6162 |
- |
- |
- |
- |
2件: 6, 8 |
906 |
Other nervous system drugs |
- |
- |
- |
- |
2件: 6, 13 |
907 |
Other parkinson's disease treatments |
- |
- |
- |
- |
1件: 6 |
908 |
Over-encapsulated entacapone tablets |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
909 |
Over-encapsulated modafinil |
Modafinil |
D01832 |
- |
- |
1件: 6 |
910 |
Oxaloacetate (oaa) |
- |
- |
- |
- |
1件: 6 |
911 |
Oxb-102 |
- |
- |
- |
- |
1件: 6 |
912 |
Oxybate |
Gamma-hydroxybutyric acid |
- |
- |
- |
3件: 6, 120, 149 |
913 |
Oxybuprocaine |
Oxybuprocaine |
D01768, D08319 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
1件: 6 |
914 |
Oxybutynin |
Oxybutynin |
D00465, D00722 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 6 |
915 |
Oxybutynin and darifenacin |
Darifenacin |
D01699, D03654 |
1件: CHRM3 |
9件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction |
1件: 6 |
916 |
Oxybutynin hydrochloride |
Oxybutynin |
D00465, D00722 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 6 |
917 |
Oxycodone |
Oxycodone |
D03783, D05312, D05462 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
7件: 6, 13, 46, 70, 226, 231, 298 |
918 |
Oxycodone/naloxone prolonged release tablets |
Oxycodone |
D03783, D05312, D05462 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
919 |
P2b001 |
- |
- |
- |
- |
1件: 6 |
920 |
P2b001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg), |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
921 |
P2b001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg), |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
922 |
Paracetamol |
Acetaminophen |
D00217 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
5件: 3, 6, 13, 35, 46 |
923 |
Parapres |
- |
- |
- |
- |
1件: 6 |
924 |
Parcopa |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
925 |
Pardaprunox |
- |
- |
- |
- |
1件: 6 |
926 |
Pardoprunox |
Pardoprunox |
D09397 |
3件: DRD2, DRD3, HTR1A |
10件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
1件: 6 |
927 |
Pardoprunox hydrochloride |
Pardoprunox |
D09397 |
3件: DRD2, DRD3, HTR1A |
10件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
1件: 6 |
928 |
Paroxetine |
Paroxetine |
D02260, D02362, D05374, D05375 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 6, 13, 46 |
929 |
Pbf-509 |
- |
- |
- |
- |
1件: 6 |
930 |
Pd patients h&y=1.5-2 medications off |
- |
- |
- |
- |
1件: 6 |
931 |
Pd patients h&y=1.5-2 medications on |
- |
- |
- |
- |
1件: 6 |
932 |
Pd patients h&y=3 medications off |
- |
- |
- |
- |
1件: 6 |
933 |
Pd patients h&y=3 medications on |
- |
- |
- |
- |
1件: 6 |
934 |
Pd vitamin supplementation |
- |
- |
- |
- |
1件: 6 |
935 |
Perampanel |
Perampanel |
D08964 |
4件: GRIA1, GRIA2, GRIA3, GRIA4 |
13件: Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Transcriptional misregulation in cancer, cAMP signaling pathway |
3件: 2, 6, 144 |
936 |
Pergolide |
Pergolide |
D00502, D08339 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
937 |
Pf-06412562 |
- |
- |
- |
- |
1件: 6 |
938 |
Pf-06649751 |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
939 |
Pf-06649751 high dose (15 mg qd) |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
940 |
Pf-06649751 low dose (1 mg qd) |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
941 |
Pf-06649751 middle dose 1 (3 mg qd) |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
942 |
Pf-06649751 middle dose 2 (7 mg qd) |
Tavapadon |
D11431 |
2件: DRD1, DRD5 |
10件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway |
1件: 6 |
943 |
Pf-06669571 |
- |
- |
- |
- |
1件: 6 |
944 |
Pharmacological treatment |
- |
- |
- |
- |
1件: 6 |
945 |
Phenylbutyrate |
Phenylbutyric acid |
D05868 |
- |
- |
10件: 2, 3, 6, 8, 93, 94, 244, 251, 297, 299 |
946 |
Piclozotan |
Piclozotan |
- |
- |
- |
1件: 6 |
947 |
Pilocarpine |
Pilocarpine |
D00525, D02200, D05478 |
2件: CHRM2, CHRM3 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
3件: 6, 53, 299 |
948 |
Pimavanserin |
Pimavanserin |
- |
- |
- |
1件: 6 |
949 |
Pimavanserin (acp-103) |
Pimavanserin |
- |
- |
- |
1件: 6 |
950 |
Pimavanserin tartrate |
Pimavanserin |
- |
- |
- |
1件: 6 |
951 |
Pimavanserin tartrate (acp-103) |
Pimavanserin |
- |
- |
- |
1件: 6 |
952 |
Pioglitazone |
Pioglitazone |
D00945, D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
953 |
Piribedil |
Piribedil |
D07305 |
2件: DRD2, DRD3 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
954 |
Piribedil (clarium) |
Piribedil |
D07305 |
2件: DRD2, DRD3 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
955 |
Pitolisant |
Pitolisant |
D10749 |
1件: HRH3 |
1件: Neuroactive ligand-receptor interaction |
1件: 6 |
956 |
Pittsburgh compound b |
Pittsburgh compound b |
- |
- |
- |
2件: 6, 127 |
957 |
Pk-merz® 200mg/500ml inj(amantadine) , normal saline 500ml inj |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 6 |
958 |
Placebo |
- |
- |
- |
- |
20件: 3, 6, 13, 14, 40, 46, 49, 50, 51, 66, 67, 79, 85, 86, 88, 96, 97, 144, 149, 226 |
959 |
Plantago ovata husk |
- |
- |
- |
- |
1件: 6 |
960 |
Positron emission tomography using [11 carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11c]-dasb) and [18 fluorine]-altanserin ([18f]-altanserin) |
Activated charcoal |
D03251 |
- |
- |
1件: 6 |
961 |
Positron emission tomography using [18 fluorine]-altanserin ([18f]-altanserin) |
- |
- |
- |
- |
1件: 6 |
962 |
Pr oxycodone |
Oxycodone |
D03783, D05312, D05462 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
963 |
Pr001a |
- |
- |
- |
- |
1件: 6 |
964 |
Pramipexol |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
965 |
Pramipexol extended release |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
966 |
Pramipexol immediate release |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
967 |
Pramipexole |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
2件: 2, 6 |
968 |
Pramipexole 0.125 mg tablets |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
969 |
Pramipexole 0.5 mg tablets |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
970 |
Pramipexole dihydrochloride |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
971 |
Pramipexole dihydrochloride extended-release tablets |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
972 |
Pramipexole dihydrochloride monohydrate |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
973 |
Pramipexole dihydrochloride monohydrate extended release |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
974 |
Pramipexole er |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
975 |
Pramipexole extended release |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
976 |
Pramipexole extended release tablet |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
977 |
Pramipexole immediate release |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
978 |
Pramipexole immediate release tablet |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
979 |
Pramipexole ir |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
980 |
Pramipexole or ropinirole |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
981 |
Pramipexole sr |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
982 |
Preladenant |
Preladenant |
D09717 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
983 |
Preladenant 10 mg tablet |
Preladenant |
D09717 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
984 |
Preladenant 2 mg tablet |
Preladenant |
D09717 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
985 |
Preladenant 5 mg tablet |
Preladenant |
D09717 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
986 |
Premarin ® |
- |
- |
- |
- |
1件: 6 |
987 |
Pridopidine |
Pridopidine |
D09953 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
2件: 6, 8 |
988 |
Prim-dj2727 |
- |
- |
- |
- |
1件: 6 |
989 |
Primary cervical dystonia (trihexyphenidyl) |
Trihexyphenidyl |
D00787, D08638 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 6 |
990 |
Probiotic |
- |
- |
- |
- |
5件: 2, 6, 96, 193, 266 |
991 |
Probiotic capsule |
- |
- |
- |
- |
1件: 6 |
992 |
Prolonged release tablet |
- |
- |
- |
- |
1件: 6 |
993 |
Prolopa® |
- |
- |
- |
- |
1件: 6 |
994 |
Propofol |
Propofol |
D00549 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
8件: 6, 21, 22, 34, 46, 84, 98, 296 |
995 |
Propofol-lipuro |
Propofol |
D00549 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 6 |
996 |
Propranolol |
Propranolol |
D00483, D08443 |
3件: ADRB1, ADRB2, ADRB3 |
11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway |
5件: 6, 158, 167, 227, 278 |
997 |
Propranolol hcl cf 40 mg tablet |
Propranolol |
D00483, D08443 |
3件: ADRB1, ADRB2, ADRB3 |
11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
998 |
Prosavin |
- |
- |
- |
- |
1件: 6 |
999 |
Proscar*30cpr riv 5mg |
Finasteride |
D00321 |
1件: SRD5A2 |
2件: Prostate cancer, Steroid hormone biosynthesis |
1件: 6 |
1000 |
Prx002 |
- |
- |
- |
- |
1件: 6 |
1001 |
Pxt002331 |
- |
- |
- |
- |
1件: 6 |
1002 |
Pxt002331 - 20mg |
- |
- |
- |
- |
1件: 6 |
1003 |
Pxt002331 - dose 1 |
- |
- |
- |
- |
1件: 6 |
1004 |
Pxt002331 - dose 2 |
- |
- |
- |
- |
1件: 6 |
1005 |
Pym50028 |
- |
- |
- |
- |
1件: 6 |
1006 |
Pyridostigmine |
Pyridostigmine |
D00487 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
4件: 3, 6, 11, 256 |
1007 |
Pyridostigmine bromide |
Pyridostigmine |
D00487 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
3件: 3, 6, 256 |
1008 |
Quetiapine |
Quetiapine |
D00458, D08456 |
2件: DRD2, HTR2A |
11件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway |
2件: 6, 13 |
1009 |
R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride |
Benzofuran |
- |
- |
- |
1件: 6 |
1010 |
R-methugdnf |
Liatermin |
D04727 |
- |
- |
1件: 6 |
1011 |
Raav-gad |
- |
- |
- |
- |
1件: 6 |
1012 |
Raclopride |
Raclopride |
- |
- |
- |
4件: 5, 6, 7, 17 |
1013 |
Ramelteon |
Ramelteon |
D02689 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
3件: 6, 8, 46 |
1014 |
Rasagilin |
- |
- |
- |
- |
2件: 5, 6 |
1015 |
Rasagilina |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1016 |
Rasagilina mesilato (12 weeks) |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1017 |
Rasagiline |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
4件: 2, 5, 6, 17 |
1018 |
Rasagiline 1 mg capsule |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1019 |
Rasagiline 1mg tablet |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1020 |
Rasagiline 2 mg tablet |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1021 |
Rasagiline mesilate |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
3件: 2, 5, 6 |
1022 |
Rasagiline mesylate |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
2件: 6, 17 |
1023 |
Rasagiline mesylate 1.0 mg |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1024 |
Rasagiline mesylate plus mirapex |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1025 |
Rasagiline mesylate with levodopa |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1026 |
Rasagiline mesylate with requip |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1027 |
Rasagiline tablets |
Rasagiline |
D02562, D08469, D10829 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1028 |
Recombinant human cerebral dopamine neurotrophic factor |
Dopamine |
D00633, D07870 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1029 |
Recombinant-methionyl human glial cell line-derived neurotrophic factor |
- |
- |
- |
- |
1件: 6 |
1030 |
Reduced glutathione |
Glutathione |
D00014, D00031 |
- |
- |
2件: 6, 299 |
1031 |
Reduced glutathione 100mg |
Glutathione |
D00014, D00031 |
- |
- |
1件: 6 |
1032 |
Reduced glutathione 200mg |
Glutathione |
D00014, D00031 |
- |
- |
1件: 6 |
1033 |
Remifentanil |
Remifentanil |
D01177, D08473 |
1件: OPRM1 |
3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
2件: 6, 70 |
1034 |
Remifentanyl |
Remifentanil |
D01177, D08473 |
1件: OPRM1 |
3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
1件: 6 |
1035 |
Reminyl retard |
- |
- |
- |
- |
1件: 6 |
1036 |
Repaglinide |
Repaglinide |
D00594 |
2件: ABCC8, KCNJ11 |
4件: ABC transporters, GnRH secretion, Insulin secretion, Type II diabetes mellitus |
2件: 6, 299 |
1037 |
Requip |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
2件: 6, 309 |
1038 |
Requip pr |
- |
- |
- |
- |
1件: 6 |
1039 |
Requip prolonged release |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1040 |
Requip xl prolonged-release |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1041 |
Requip*21cpr 5mg |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1042 |
Requip*28cpr 8mg r.p. |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1043 |
Requip-lp |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1044 |
Requip-modutab |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1045 |
Requip-modutab , 2mg |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1046 |
Requip-modutab , 4mg |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1047 |
Requip-modutab , 8mg |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1048 |
Requip-modutab, 2mg |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1049 |
Requip-modutab, 4mg |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1050 |
Requip-modutab, 8mg |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1051 |
Resistant maltodextrin |
Maltodextrin |
D02329 |
- |
- |
1件: 6 |
1052 |
Resistant starch |
- |
- |
- |
- |
1件: 6 |
1053 |
Rifampicin |
Rifampicin |
D00211 |
- |
- |
4件: 6, 17, 46, 299 |
1054 |
Rifampin |
Rifampicin |
D00211 |
- |
- |
5件: 6, 13, 84, 86, 299 |
1055 |
Rifampin 300mg bid + istradefylline 40mg day 8 only |
Istradefylline |
D04641 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
1056 |
Rifaximin |
Rifaximin |
D02554 |
- |
- |
5件: 6, 96, 97, 99, 296 |
1057 |
Rifaximin 550 mg |
Rifaximin |
D02554 |
- |
- |
1件: 6 |
1058 |
Ritalin |
Methylphenidate |
D01296, D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
2件: 6, 13 |
1059 |
Rivastigmine |
Rivastigmine |
D02558, D03822 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
3件: 5, 6, 13 |
1060 |
Rivastigmine capsule |
Rivastigmine |
D02558, D03822 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 6 |
1061 |
Rivastigmine patch 9.5 cm2 |
Rivastigmine |
D02558, D03822 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
1件: 6 |
1062 |
Rivastigmine transdermal patch |
Rivastigmine |
D02558, D03822 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
2件: 6, 13 |
1063 |
Rm-131 |
- |
- |
- |
- |
1件: 6 |
1064 |
Ro7046015 |
- |
- |
- |
- |
1件: 6 |
1065 |
Rop+l-dopa |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1066 |
Ropinirole |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
3件: 6, 74, 309 |
1067 |
Ropinirole (as hydrochloride) |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1068 |
Ropinirole controlled-release (requip cr) for rls |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1069 |
Ropinirole cr 2mg tablet |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1070 |
Ropinirole cr 8mg tablet |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1071 |
Ropinirole hydrochloride |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
2件: 6, 309 |
1072 |
Ropinirole hydrochloride extended-release tablet |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1073 |
Ropinirole hydrochloride extended-release tablet placebo |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1074 |
Ropinirole hydrochloride prolonged release |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1075 |
Ropinirole immediate release |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1076 |
Ropinirole implant |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1077 |
Ropinirole ir |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1078 |
Ropinirole ir tablets |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1079 |
Ropinirole monotherapy |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1080 |
Ropinirole oral product |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1081 |
Ropinirole pr |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1082 |
Ropinirole pr, 2mg |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1083 |
Ropinirole pr/xr |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1084 |
Ropinirole pr/xr tablets |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1085 |
Ropinirole prolonged release |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1086 |
Ropinirole prolonged release/extended release(pr/xr) |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1087 |
Ropinirole xl |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1088 |
Ropinirole xl (formerly cr) |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1089 |
Ropinirole/l-dopa |
Ropinirole |
D00784, D08489 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1090 |
Rosuvastatin |
Rosuvastatin |
D01915, D08492 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
8件: 6, 46, 49, 51, 79, 96, 271, 299 |
1091 |
Rotigotin |
- |
- |
- |
- |
1件: 6 |
1092 |
Rotigotina |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1093 |
Rotigotine |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1094 |
Rotigotine (reference product pr 2.1.1) |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1095 |
Rotigotine (test product pr 2.3.1) |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1096 |
Rotigotine hydrochloride |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1097 |
Rotigotine nasal spray |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1098 |
Rotigotine transdermal patch |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1099 |
Rotigotine transdermal patch 2mg/24h(10cm2) |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1100 |
Rotigotine transdermal patch 4mg/24h (20cm2) |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1101 |
Rotigotine transdermal patch 6mg/24h (30cm2) |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1102 |
Rotigotine transdermal patch 8mg/24h (40cm2) |
Rotigotine |
D05768 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1103 |
Rozerem |
Ramelteon |
D02689 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
1件: 6 |
1104 |
Rq-00000010 |
- |
- |
- |
- |
1件: 6 |
1105 |
Rvg 55618 |
- |
- |
- |
- |
1件: 6 |
1106 |
Rvt-101 35 mg |
- |
- |
- |
- |
1件: 6 |
1107 |
Rytary 145 mg |
- |
- |
- |
- |
1件: 6 |
1108 |
Rytary 195 mg |
- |
- |
- |
- |
1件: 6 |
1109 |
S 90049 |
- |
- |
- |
- |
1件: 6 |
1110 |
S 90049 - f36 |
- |
- |
- |
- |
1件: 6 |
1111 |
S 90049 - f38 |
- |
- |
- |
- |
1件: 6 |
1112 |
S.c. apomorphine |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1113 |
Safety observation |
- |
- |
- |
- |
1件: 6 |
1114 |
Safinamida |
Safinamide |
D10158 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1115 |
Safinamide |
Safinamide |
D10158 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
2件: 6, 17 |
1116 |
Safinamide + levodopa |
Safinamide |
D10158 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1117 |
Safinamide metansolfonato (12 weeks) |
Safinamide |
D10158 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1118 |
Safinamide methanesulfonate |
Safinamide |
D10158 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
2件: 6, 17 |
1119 |
Safinamide methanesulfonate 100mg |
Safinamide |
D10158 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1120 |
Safinamide methanesulfonate 150mg |
Safinamide |
D10158 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1121 |
Safinamide methansulfonate |
Safinamide |
D10158 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1122 |
Safinamide, mao-b inhibitor |
Safinamide |
D10158 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1123 |
Sage |
Sage |
- |
- |
- |
2件: 6, 8 |
1124 |
Sage leaf |
Sage |
- |
- |
- |
1件: 6 |
1125 |
Sage-217 |
Sage |
- |
- |
- |
1件: 6 |
1126 |
Saline |
Sodium chloride |
D02056 |
- |
- |
10件: 6, 13, 17, 53, 67, 78, 86, 97, 168, 299 |
1127 |
Saline intranasal delivery |
- |
- |
- |
- |
1件: 6 |
1128 |
Sam-e |
Ademetionine |
D07128 |
- |
- |
1件: 6 |
1129 |
Same |
Ademetionine |
D07128 |
- |
- |
15件: 6, 14, 22, 43, 44, 46, 47, 49, 50, 60, 84, 93, 96, 97, 172 |
1130 |
Saracatinib |
Saracatinib |
D09664 |
2件: ABL1, SRC |
45件: Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection |
2件: 6, 89 |
1131 |
Sarcosine |
Sarcosine |
- |
- |
- |
1件: 6 |
1132 |
Sarcosine capsule |
Sarcosine |
- |
- |
- |
1件: 6 |
1133 |
Sargramostim |
Sargramostim |
D05803 |
1件: CSF2RA |
4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
6件: 6, 28, 60, 62, 96, 229 |
1134 |
Sarizotan |
Sarizotan |
- |
- |
- |
2件: 6, 156 |
1135 |
Sarizotan hc1 |
Sarizotan |
- |
- |
- |
1件: 6 |
1136 |
Sarizotan hcl |
Sarizotan |
- |
- |
- |
1件: 6 |
1137 |
Sarizotan hydrochloride |
Sarizotan |
- |
- |
- |
2件: 6, 156 |
1138 |
Sch 420814 |
- |
- |
- |
- |
1件: 6 |
1139 |
Sch 420814 10 mg |
- |
- |
- |
- |
1件: 6 |
1140 |
Sch 420814 100 mg |
- |
- |
- |
- |
1件: 6 |
1141 |
Sch 900800 |
- |
- |
- |
- |
1件: 6 |
1142 |
Selegiline |
Selegiline |
D00785, D03731 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1143 |
Selegiline hcl 5 pch |
Selegiline |
D00785, D03731 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1144 |
Semaglutide |
Semaglutide |
D10025 |
1件: GLP1R |
3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
1件: 6 |
1145 |
Semi continuous intra-oral administration of ld/cd |
- |
- |
- |
- |
1件: 6 |
1146 |
Sep-363856 |
- |
- |
- |
- |
1件: 6 |
1147 |
Ser-214 |
- |
- |
- |
- |
1件: 6 |
1148 |
Serine |
Serine |
D00016 |
- |
- |
3件: 2, 6, 86 |
1149 |
Seroquel |
Quetiapine |
D00458, D08456 |
2件: DRD2, HTR2A |
11件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway |
1件: 6 |
1150 |
Sertraline |
Sertraline |
D00825, D02360 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
2件: 6, 206 |
1151 |
Sevoflurane |
Sevoflurane |
D00547 |
- |
- |
5件: 6, 21, 22, 98, 296 |
1152 |
Sifol |
- |
- |
- |
- |
1件: 6 |
1153 |
Sifrol |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1154 |
Sifrol 0,088 |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1155 |
Sifrol 0,18 |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1156 |
Sifrol 0,35 |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1157 |
Sifrol 0,7 |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1158 |
Sifrol, 0,35 mg tablette |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1159 |
Sifrol, 0,70 mg tablette |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1160 |
Sifrol® |
- |
- |
- |
- |
1件: 6 |
1161 |
Sildenafil |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
15件: 6, 46, 50, 51, 85, 86, 113, 210, 211, 212, 225, 226, 278, 294, 299 |
1162 |
Silodosin |
Silodosin |
D01965 |
1件: ADRA1A |
7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 6 |
1163 |
Simvastatin |
Simvastatin |
D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
1164 |
Simvastatine |
Simvastatin |
D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
2件: 6, 13 |
1165 |
Sinemet |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1166 |
Sinemet (comparator) |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1167 |
Sinemet (levodopa/carbidopa) |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1168 |
Sinemet 100 mg + 25 mg compresse |
- |
- |
- |
- |
1件: 6 |
1169 |
Sinemet 125 mg |
- |
- |
- |
- |
1件: 6 |
1170 |
Sinemet 200mg/50mg |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1171 |
Sinemet 25-100 |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1172 |
Sinemet 25/100 |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1173 |
Sinemet cr |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1174 |
Sinemet cr 25mg-100mg extended-release tablet |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1175 |
Sinemet ir |
- |
- |
- |
- |
1件: 6 |
1176 |
Sinemet plus |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1177 |
Sinemet plus (levodopa/carbidopa) |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1178 |
Sinemet*50cpr 100mg+25mg |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1179 |
Sinemet® |
- |
- |
- |
- |
1件: 6 |
1180 |
Sinemet® 100/25 |
- |
- |
- |
- |
1件: 6 |
1181 |
Sinemet® 100/25 mg |
- |
- |
- |
- |
1件: 6 |
1182 |
Sinemet® controlled release (carbidopa/levodopa) |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1183 |
Sinemet® cr |
- |
- |
- |
- |
1件: 6 |
1184 |
Sinemet® cr 100/25 |
- |
- |
- |
- |
1件: 6 |
1185 |
Sinemet® plus 25 mg/100 mg tablets |
- |
- |
- |
- |
1件: 6 |
1186 |
Sinemet®-plus tablets |
- |
- |
- |
- |
1件: 6 |
1187 |
Sirio*30cpr eff 25mg+100mg |
- |
- |
- |
- |
1件: 6 |
1188 |
Sk&f101468 |
- |
- |
- |
- |
1件: 6 |
1189 |
Slv308 |
- |
- |
- |
- |
1件: 6 |
1190 |
Slv308 (mono) hydrochlori |
- |
- |
- |
- |
1件: 6 |
1191 |
Slv308 (mono) hydrochloride |
- |
- |
- |
- |
1件: 6 |
1192 |
Slv308 hydrochloride |
- |
- |
- |
- |
1件: 6 |
1193 |
Smilagenin |
Smilagenin |
- |
- |
- |
1件: 6 |
1194 |
Snd 919 |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1195 |
Snd 919 cl2 y |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1196 |
Snd 919 cl2y |
Pramipexole |
D00559, D05575 |
3件: DRD2, DRD3, DRD4 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1197 |
Snn0031 |
- |
- |
- |
- |
1件: 6 |
1198 |
Sodium chloride |
Sodium chloride |
D02056 |
- |
- |
13件: 6, 11, 13, 14, 34, 46, 51, 168, 193, 227, 228, 288, 299 |
1199 |
Sodium oxybate |
Sodium oxybate |
D05866 |
- |
- |
3件: 6, 120, 149 |
1200 |
Solifenacin |
Solifenacin |
D01269, D08522 |
1件: CHRM3 |
9件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction |
1件: 6 |
1201 |
Solifenacin succinate (vesicare) |
Solifenacin |
D01269, D08522 |
1件: CHRM3 |
9件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction |
1件: 6 |
1202 |
Solu-cortef |
Hydrocortisone succinate |
D01442 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
3件: 6, 81, 83 |
1203 |
Solu-cortef, powder for solution for injection, 100mg, and 'act-o-vial' |
Hydrocortisone succinate |
D01442 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 6 |
1204 |
Soy protein |
- |
- |
- |
- |
2件: 6, 96 |
1205 |
Spheramine (bay86-5280) |
- |
- |
- |
- |
1件: 6 |
1206 |
Spm 962 |
- |
- |
- |
- |
1件: 6 |
1207 |
Spm962 |
- |
- |
- |
- |
1件: 6 |
1208 |
Sqjz herbal mixtures |
- |
- |
- |
- |
1件: 6 |
1209 |
Sr57667b |
- |
- |
- |
- |
1件: 6 |
1210 |
Stalevo |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1211 |
Stalevo (levodopa/ carbidopa/ entacapone) |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
1212 |
Stalevo (levodopa/carbidopa/entacapona) |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1213 |
Stalevo 100 |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1214 |
Stalevo 100 mg/ 25 mg/ 200 mg filmtabletten |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1215 |
Stalevo 100/25/200 mg |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1216 |
Stalevo 150 |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1217 |
Stalevo 150/37.5/200 mg |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1218 |
Stalevo*100cpr 100/25/200mg |
- |
- |
- |
- |
1件: 6 |
1219 |
Stalevo*100cpr 50/12,5/200mg |
- |
- |
- |
- |
1件: 6 |
1220 |
Stalevo® |
- |
- |
- |
- |
1件: 6 |
1221 |
Standard ld/cd |
- |
- |
- |
- |
1件: 6 |
1222 |
Standard of care |
- |
- |
- |
- |
8件: 6, 13, 14, 49, 51, 64, 79, 85 |
1223 |
Stilnoct |
- |
- |
- |
- |
1件: 6 |
1224 |
Strattera |
Atomoxetine |
D02574, D07473 |
1件: SLC6A2 |
1件: Synaptic vesicle cycle |
1件: 6 |
1225 |
Study drug |
- |
- |
- |
- |
2件: 6, 13 |
1226 |
Subcutaneous apomorphine |
Apomorphine |
D02004, D07460 |
2件: DRD1, DRD2 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1227 |
Subcutaneous hydrocortisone 10mg |
Hydrocortisone |
D00088 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 6 |
1228 |
Subjects will undergo the 123-i ibvm imaging visit |
- |
- |
- |
- |
1件: 6 |
1229 |
Sugar pill |
- |
- |
- |
- |
7件: 6, 49, 67, 70, 86, 206, 226 |
1230 |
Sulfate |
Sulfate ion |
- |
- |
- |
22件: 2, 6, 11, 13, 26, 34, 36, 46, 49, 60, 61, 64, 66, 79, 86, 96, 222, 226, 265, 296, 297, 299 |
1231 |
Sumanirole |
Sumanirole |
- |
- |
- |
1件: 6 |
1232 |
Supplementation |
- |
- |
- |
- |
1件: 6 |
1233 |
Supressi. t-diet plus range |
- |
- |
- |
- |
1件: 6 |
1234 |
Suvorexant |
Suvorexant |
D10082 |
2件: HCRTR1, HCRTR2 |
1件: Neuroactive ligand-receptor interaction |
3件: 5, 6, 13 |
1235 |
Syn120 |
- |
- |
- |
- |
1件: 6 |
1236 |
Tadalafil |
Tadalafil |
D02008 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
6件: 6, 51, 75, 84, 86, 113 |
1237 |
Talampanel |
Talampanel |
D02696 |
4件: GRIA1, GRIA2, GRIA3, GRIA4 |
13件: Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Transcriptional misregulation in cancer, cAMP signaling pathway |
2件: 2, 6 |
1238 |
Tasmar |
Tolcapone |
D00786 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
2件: 6, 28 |
1239 |
Tch346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt) |
Hydrogen |
- |
- |
- |
1件: 6 |
1240 |
Td-9855 |
- |
- |
- |
- |
2件: 6, 17 |
1241 |
Technetium (99mtc) exametazime |
Exametazime |
D01109 |
- |
- |
1件: 6 |
1242 |
Terazosin |
Terazosin |
D00610, D08569 |
3件: ADRA1A, ADRA1B, ADRA1D |
7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 6 |
1243 |
Terazosin 5 mg |
Terazosin |
D00610, D08569 |
3件: ADRA1A, ADRA1B, ADRA1D |
7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 6 |
1244 |
Tesofensine |
Tesofensine |
- |
- |
- |
2件: 6, 193 |
1245 |
Thn02 |
- |
- |
- |
- |
1件: 6 |
1246 |
Thn102 dosage a |
- |
- |
- |
- |
1件: 6 |
1247 |
Thn102 dosage b |
- |
- |
- |
- |
1件: 6 |
1248 |
Thn102 dosage c |
- |
- |
- |
- |
1件: 6 |
1249 |
Tigan® |
- |
- |
- |
- |
1件: 6 |
1250 |
Tolcapon |
Tolcapone |
D00786 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
1251 |
Tolcapone |
Tolcapone |
D00786 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
3件: 6, 28, 127 |
1252 |
Topiramate |
Topiramate |
D00537 |
36件: CA2, CA4, CACNA1C, CACNA1D, CACNA1F, CACNA1S, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
48件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Arrhythmogenic right ventricular cardiomyopathy (ARVC), Bile secretion, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Collecting duct acid secretion, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term depression, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Nitrogen metabolism, Oxytocin signaling pathway, Pancreatic secretion, Proximal tubule bicarbonate reclamation, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Transcriptional misregulation in cancer, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
5件: 6, 140, 144, 156, 193 |
1253 |
Topiramate (drug) |
Topiramate |
D00537 |
36件: CA2, CA4, CACNA1C, CACNA1D, CACNA1F, CACNA1S, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
48件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Arrhythmogenic right ventricular cardiomyopathy (ARVC), Bile secretion, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Collecting duct acid secretion, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term depression, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Nitrogen metabolism, Oxytocin signaling pathway, Pancreatic secretion, Proximal tubule bicarbonate reclamation, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Transcriptional misregulation in cancer, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 6 |
1254 |
Tozadenant |
Tozadenant |
D10174 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
1255 |
Tozadenant (syn115) 120 mg bid |
Tozadenant |
D10174 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
1256 |
Tozadenant (syn115) 180 mg bid |
Tozadenant |
D10174 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
1257 |
Tozadenant (syn115) 240 mg bid |
Tozadenant |
D10174 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
1258 |
Tozadenant (syn115) 60 mg bid |
Tozadenant |
D10174 |
1件: ADORA2A |
7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
1件: 6 |
1259 |
Traditional chinese medicinal mixture (composed of roucongrong and adjuvant) |
- |
- |
- |
- |
1件: 6 |
1260 |
Transdermal nicotine |
Nicotine |
D03365, D05156, D05157 |
16件: CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG |
5件: Calcium signaling pathway, Chemical carcinogenesis, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction |
1件: 6 |
1261 |
Trigel |
- |
- |
- |
- |
1件: 6 |
1262 |
Trihexyphenidyl |
Trihexyphenidyl |
D00787, D08638 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
2件: 5, 6 |
1263 |
Trimethobenzamide |
Trimethobenzamide |
D02733, D08643 |
- |
- |
1件: 6 |
1264 |
Trimethobenzamide hydrochloride |
Trimethobenzamide |
D02733, D08643 |
- |
- |
1件: 6 |
1265 |
Trivastal |
Piribedil |
D07305 |
2件: DRD2, DRD3 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1266 |
Tropicamide |
Tropicamide |
D00397 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
2件: 6, 19 |
1267 |
Tryptophan |
L-tryptophan |
D00020 |
- |
- |
1件: 6 |
1268 |
Tryptophan (trp) depletion |
L-tryptophan |
D00020 |
- |
- |
1件: 6 |
1269 |
Tvp-1012 |
- |
- |
- |
- |
1件: 6 |
1270 |
Tvp-1012 (1 mg/day) with levodopa |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1271 |
Tvp-1012 0.5mg |
- |
- |
- |
- |
1件: 6 |
1272 |
Tvp-1012 1mg |
- |
- |
- |
- |
1件: 6 |
1273 |
Tvp-1012 1mg with levodopa |
Levodopa |
D00059 |
5件: DRD1, DRD2, DRD3, DRD4, DRD5 |
11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 6 |
1274 |
Tyrosine |
Tyrosine |
D00022 |
- |
- |
3件: 6, 86, 111 |
1275 |
Ub-312 |
- |
- |
- |
- |
1件: 6 |
1276 |
Ubiquinol |
Ubiquinol |
- |
- |
- |
3件: 6, 8, 17 |
1277 |
Urate |
Uric acid |
- |
- |
- |
1件: 6 |
1278 |
Ursodeoxycholic acid |
Ursodeoxycholic acid |
D00734 |
1件: NR1H4 |
1件: Bile secretion |
8件: 6, 67, 84, 93, 94, 95, 96, 97 |
1279 |
V1512 |
- |
- |
- |
- |
1件: 6 |
1280 |
V1512 and entacapone |
Entacapone |
D00781 |
1件: COMT |
4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
1件: 6 |
1281 |
V81444 |
- |
- |
- |
- |
1件: 6 |
1282 |
Valerian |
Valerian |
- |
- |
- |
1件: 6 |
1283 |
Varenicline |
Varenicline |
D08669 |
2件: CHRNA4, CHRNB2 |
3件: Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction |
2件: 6, 18 |
1284 |
Varenicline tartrate |
Varenicline |
D08669 |
2件: CHRNA4, CHRNB2 |
3件: Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction |
1件: 6 |
1285 |
Variation of behaviors of parkinson's disease |
- |
- |
- |
- |
1件: 6 |
1286 |
Vehicle |
- |
- |
- |
- |
4件: 6, 36, 160, 192 |
1287 |
Venlafaxine |
Venlafaxine |
D00821, D08670 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 6, 13, 46 |
1288 |
Vineuro |
- |
- |
- |
- |
1件: 6 |
1289 |
Vitamin b12 |
Cyanocobalamin |
D00166, D03615, D03616, D03617 |
- |
- |
4件: 6, 201, 229, 299 |
1290 |
Vitamin b12 supplementation |
Cyanocobalamin |
D00166, D03615, D03616, D03617 |
- |
- |
1件: 6 |
1291 |
Vitamin b6 |
Pyridoxine |
D02179, D08454 |
- |
- |
1件: 6 |
1292 |
Vitamin d3 |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
11件: 6, 13, 20, 46, 49, 53, 60, 65, 96, 97, 299 |
1293 |
Vitamin d3 - high dose |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 6 |
1294 |
Vitamin e |
Vitamin e |
D02331 |
- |
- |
11件: 2, 6, 13, 20, 46, 90, 96, 97, 206, 299, 317 |
1295 |
Viusid/alzer |
- |
- |
- |
- |
1件: 6 |
1296 |
Vr040 |
- |
- |
- |
- |
1件: 6 |
1297 |
Vr040/aspirair® inhaler |
- |
- |
- |
- |
1件: 6 |
1298 |
Vy-aadc01 |
- |
- |
- |
- |
1件: 6 |
1299 |
Vy-aadc02 |
- |
- |
- |
- |
1件: 6 |
1300 |
Warfarin |
Warfarin |
D00564, D01280, D08682 |
2件: NQO1, VKORC1 |
5件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
10件: 6, 8, 13, 19, 46, 49, 66, 85, 88, 96 |
1301 |
Water |
Water |
D00001 |
- |
- |
18件: 2, 5, 6, 13, 17, 19, 35, 46, 53, 57, 63, 65, 67, 84, 97, 226, 278, 299 |
1302 |
Whey protein |
- |
- |
- |
- |
2件: 6, 96 |
1303 |
White chocolate (0% cocoa) |
Cocoa |
- |
- |
- |
1件: 6 |
1304 |
Wuling powder |
- |
- |
- |
- |
1件: 6 |
1305 |
Xadago |
Safinamide |
D10158 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1306 |
Xadago (safinamide) |
Safinamide |
D10158 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1307 |
Xc130-a10h |
- |
- |
- |
- |
1件: 6 |
1308 |
Xeomin |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
7件: 5, 6, 7, 13, 15, 17, 113 |
1309 |
Xiaoyao pill |
- |
- |
- |
- |
1件: 6 |
1310 |
Xp21279 |
- |
- |
- |
- |
1件: 6 |
1311 |
Xp21279 and carbidopa (experimental) |
Carbidopa |
D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1312 |
Zelapar |
Selegiline |
D00785, D03731 |
1件: MAOB |
13件: Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
1件: 6 |
1313 |
Zoledronic acid |
Zoledronic acid |
D01968, D06378, D06379, D08689 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
9件: 6, 13, 46, 93, 95, 96, 274, 299, 333 |
1314 |
Zoledronic acid 5mg/bag 100ml inj |
Zoledronic acid |
D01968, D06378, D06379, D08689 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 6 |
1315 |
Zolmitriptan |
Zolmitriptan |
D00415 |
2件: HTR1B, HTR1D |
4件: Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
1件: 6 |
1316 |
Zolpidem |
Zolpidem |
D00706, D08690 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
2件: 5, 6 |
1317 |
Zolpidem first dose |
Zolpidem |
D00706, D08690 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 6 |
1318 |
Zolpidem second dose |
Zolpidem |
D00706, D08690 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 6 |
1319 |
Zolpidem tartrate |
Zolpidem |
D00706, D08690 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 6 |
1320 |
Zonegran |
Zonisamide |
D00538 |
8件: CACNA1G, CACNA1H, CACNA1I, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
11件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dopaminergic synapse, GnRH secretion, MAPK signaling pathway, Taste transduction, Type II diabetes mellitus |
1件: 6 |
1321 |
Zonisamide |
Zonisamide |
D00538 |
8件: CACNA1G, CACNA1H, CACNA1I, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
11件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dopaminergic synapse, GnRH secretion, MAPK signaling pathway, Taste transduction, Type II diabetes mellitus |
1件: 6 |
1322 |
Zopiclone |
Zopiclone |
D01372 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 6 |